A Randomised Clinical Study of Alfacalcidol and Paricalcitol

Two vitamin D analogs for treatment of secondary hyperparathyroidism in chronic hemodialysis patients

Ditte Hansen, MD

This review has been accepted as a thesis together with three previously published papers by University of Copnehagen 20th of August 2011 and defended on 8th of October 2011

Tutors: Knud Rasmussen and Lisbet Brandi

Official opponents: Klaus Ølgaard, Jens Dam Jensen and Tobias Larsson

Correspondence: Department,of Medicine, Roskilde Hospital, Koegevej 7-13, 4000 Roskilde, Denmark

E-mail: dittehansen@dadlnet.dk

THE THREE ORIGINAL PAPERS ARE

Paper I
Hansen D, Brandi L, Rasmussen K. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol. BMC Nephrol 2009;10:28

Paper II
Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, et al. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int 2011 Oct;80(8):841-50

Paper III
Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 2011 Dec 1.

BACKGROUND
CHRONIC KIDNEY DISEASE - MINERAL AND BONE DISORDER (CKD-MBD)

Definition
In Denmark, the prevalence of dialysis patients was 2650 in 2009.1 Disturbances in the mineral metabolism develop as renal insufficiency progress, beginning in chronic kidney disease (CKD) stage 3, and are present in most patients when reaching dialysis. Ninety-six % of the hemodialysis patients (n = 76) in our department were at the time of screening for participants to the present study, treated for disturbances in the mineral metabolism. These disturbances are associated with alterations in bone morphology, termed renal osteodystrophy and increased risk of skeletal fracture. The disturbances in the mineral metabolism are also associated with vascular and other soft tissue calcification, and in turn increased cardiovascular morbidity and mortality. The systemic disorder consisting of mineral disturbances, bone abnormalities and extraskeletal calcification, is defined as Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).2

Secondary hyperparathyroidism and renal osteodystrophy
When CKD develops 1,25-dihydroxyvitamin D levels decrease.3 This is partly due to decreased availability of the precursor 25-hydroxyvitamin D. The most important reason is the decreased 1α-hydroxylation of 25-hydroxyvitamin D in the kidney. As the kidney mass declines the amount of 1α-hydroxylase decreases and as glomerular filtration rate (GFR) declines the delivery of vitamin D to 1α-hydroxylation via glomerular filtration declines.4 Apparently, fibroblast growth factor 23 (FGF23) increases in CKD patients before changes in calcium, phosphate and parathyroid hormone (PTH) develops,5 and the rise is associated with the appearance of deficiency in 1,25-dihydroxyvitamin D, which could be induced by the rising FGF23.6 Phosphate and C-terminal PTH fragments increases when CKD develops and has the potential to further decrease the activity of 1α-hydroxylase.7;8

Secondary hyperparathyroidism (SHPT) is characterised by increased serum levels of PTH and parathyroid hyperplasia. Several stimuli may contribute to the development of secondary hyperparathyroidism in patients with chronic kidney disease. Hyperphosphatemia caused by decreased renal phosphate excretion. Hypocalcemia caused by low levels of 1,25-dihydroxyvitamin D and hyperphosphatemia. In addition, the expression of the calcium-sensing-receptor (CaSR) are decreased in uraemia, probably as a result of hyperplasia and reduced 1,25-dihydroxyvitamin D, leading to impaired calcium sensitivity of the parathyroid glands.9 The 1,25-dihydroxyvitamin D deficiency induces SHPT because of the removal of a direct inhibition of PTH transcription and indirectly through a decreased calcium level. The synthesis of the vitamin D receptor (VDR) declines and the affinity of the VDR for the vitamin D response element decreases as CKD progress, which may increase PTH even in early CKD with normal 1,25-dihydroxyvitamin D level.9;10 Apparently, uraemia per se also induce a stability of PTH mRNA leading to decreased degradation and thereby increased PTH synthesis.11

Renal osteodystrophy covers different histological patterns of bone abnormalities in chronic kidney disease. The three main conditions are 1: Osteitis fibrosa cystica with high bone turnover and elevated levels of PTH. 2: Adynamic bone disease, osteomalacia with low bone turnover and decreased levels of PTH. 3: Mixed lesions. The gold standard for description of bone turnover are bone biopsy. 12;13 Bone biopsy is seldom used in Denmark. At the moment, PTH remains the single most useful biochemical parameter predicting bone histology, and changes in PTH is used for guidance, when treating renal osteodystrophy.14;15 Low and/or high PTH has been associated with increased incidence of fracture in CKD patients.16;17 and a case-control study found a decreased fracture incidence after parathyroidectomy.18 Whether this relation is disrupted by new treatment modalities and PTH assays, has recently been suggested.2;19

Chronic kidney disease and cardiovascular disease
Patients with chronic kidney disease have increased mortality compared to the general population. In Denmark, the mortality rate in hemodialysis patients in 2009 were 21.2 per 100 person-year (95% CI: 19.2-23.2).1 In 1998 Foley et al. described a 10-20 fold increased risk of cardiovascular mortality in dialysis patients,20 and in 2004 Go et al. described that the risk of mortality and cardiovascular disease increased with declining kidney function, beginning at GFR below 60 ml per min per 1.73m2.21 Traditional risk factors, such as hypertension, dyslipidemia and diabetes are involved in the pathogenesis of cardiovascular disease in CKD patients. But non-traditional risk factors are also present.22 Observational trials have found the disturbances in the mineral metabolism to be related to the increased risk of cardiovascular disease and mortality.23-33

Calcium, phosphate and parathyroid hormone
Hyperphosphatemia is associated with cardiovascular disease,24;27;32 cardiovascular mortality,24;25;27;30;32;33 and is a strong predictor of all-cause mortality,23;24;27;29-33 in CKD 3-5D patients and elevated calcium levels are associated with increased mortality in CKD 3-5D patients.24;26;28 Experimental data support this association, as phosphate and calcium are potent inducers of vascular calcification.34-36 Even in young 20-30 years old hemodialysis-treated adults, Goodman et al. demonstrated coronary-artery calcification with a high progression rate, which was correlated to the circulating level of phosphate, calcium x phosphate product and calcium intake.37 Coronary artery calcification correlates with the presence of cardiovascular disease and is associated with increased levels of calcium and phosphate.38 Likewise, arterial media calcification, a strong predictor of cardiovascular mortality, is strongly associated with increasing levels of calcium and phosphate.39 On the other hand, very low calcium levels also increases the short-term mortality risk,28;33;40 perhaps by increasing neuromuscular excitability and risk of sudden death.41

Elevated PTH is associated with increased cardiovascular mortality,25;30 and over-all mortality 24;29;30;33 in CKD 5D. PTH is associated with left ventricular hypertrophy,42 and can induce cardiomyocyte hypertrophy,43 which may be the underlying mechanism. Opposite, very low PTH is also associated with increased cardiovascular,25;30 and over-all mortality,30;44 perhaps related to the presence of low bone turn-over disease, increasing the risk of vascular calcification45 due to less skeletal buffer of calcium. Furthermore, PTH could be a marker of malnutrition.46 Based on cut-off values from observational studies, guidelines propose target levels for phosphate, calcium and PTH levels.2;47;48 These guidelines are stressed by Palmer et al. in a recent systematic review and meta-analysis of observational trials.49 Palmer et al. found an association between phosphate levels and mortality, whereas no significant association between PTH and mortality, or calcium levels and mortality was found. Importantly, no interventional studies has addressed whether these targets improves patient related clinical outcomes, and placebo controlled trials of interventions including phosphate-binders, vitamin D analogs and calcimimetics and their effect on patient-level outcome are certainly needed.

Vitamin D
Low levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D are associated with increased risk of mortality during the first three month in incident hemodialysis patients,50 increased cardiovascular disease, and mortality in newly referred patients to an Italian nephrology department,51 and have a graded relation to mortality in CKD-non-D.52 Likewise, in the general population cohorts (Framingham and NHANES) an association between low levels of 25-hydroxyvitamin D and cardiovascular morbidity and mortality has been found.53-55
This raises the question whether treatment with vitamin D will improve the cardiovascular risk profile. Interestingly, many observational studies in CKD patients have found an increased survival and reduced cardiovascular morbidity in patients treated with vitamin D analogs (**Table 1**).

There may be an effect of vitamin D itself, as the increased survival was found even after adjustment for disturbances in the mineral metabolism.58 Increasing doses of vitamin D attenuated the improved survival in two dose studies,26;61 leaving the question whether active vitamin D possess a U shaped response curve. However, it may be the high PTH that triggers the high dose vitamin D analog, which is harmful. Indeed, the ratio of paricalcitol/PTH has been shown to be positively associated with an increased survival.65 Teng et al. found an improved survival with paricalcitol a newer vitamin D analog compared to the older analog calcitriol.56 This difference was also found in a cohort study by Tentori et al., but significance disappeared after adjustment for laboratory values and clinic standardised mortality.59

There are no interventional studies to address the question whether vitamin D and its analogs improve survival and reduce cardiovascular risk in CKD patients. A Cochrane systematic review of patients requiring dialysis included 76 randomised controlled trials, each relatively small with a maximum of 266 participating patients. Only five small studies were found to report survival data, and there was not enough power in the meta-analysis to describe the effect of vitamin D on cardiovascular disease and death.69 The Cochrane group also performed a meta-analysis in patients not requiring dialysis. 16 studies were included, only four reporting survival data with a maximum of 220 participants. No survival difference or difference in other patient-centered endpoints was found, although this small amount of data did not have enough power to adequately detect an eventual difference.70 However, a metaanalysis from 2007 of 18 randomised controlled trials in people with and without renal disease, did find a reduced 0.93 (95% CI: 0.87-0.99) relative risk of death in vitamin D treated compared to untreated patients. The patients in the analysed studies were mostly older and institutionalised persons, with a follow-up of six month to seven years. No cause specific mortality reduction could be identified.71 A meta-analysis from 2010, also encompassing people with and without renal disease, analysed the effect of vitamin D, vitamin D plus calcium, and calcium on cardiovascular events. Only two studies with vitamin D

only, were included. Any difference compared to placebo could not be identified in any of the groups.72

Fibroblast growth factor 23
Fibroblast growth factor 23 (FGF23) is a recently discovered endocrine factor, a glycoprotein, synthesized primarily in the skeleton in osteocytes and osteoblasts.73 Klotho is synthesised in the distal tubular cells of the kidney, in the parathyroid glands, and in the choroid plexus,74;75 and is an obligatory co-receptor for the binding of FGF23 to the FGF receptors (FGFR)

FGF23 increases renal phosphate excretion due to inappropriate phosphate reabsorption in the proximal tubules by decreasing the expression and insertion of the Na/Pi co-transporter.73;76 Klotho-FGF23 system also decreases the level of 1,25-dihydroxyvitamin D by decreasing the expression of 1α-hydroxylase in the proximal tubules and increasing the expression of 24-hydroxylase in the distal tubules.77;78 FGF23 suppresses PTH secretion and parathyroid cell proliferation, and increases CaSR and VDR expression in normal parathyroid glands.74;79 FGF23 does not have the same effect in uremic hyperplastic glands,80;81 probably because of reduced expression of FGFR1 and Klotho protein.82

Circulating FGF23 rises progressively as kidney function declines,83 and dialysis patients have remarkably high FGF23 levels up to 1000 fold higher than healthy individuals.84 The mechanisms responsible for the elevated FGF23 in CKD patients is not precisely known. Oral chronic phosphate load and 1,25-dihydroxyvitamin D independently increase circulating FGF23.85-89 The rise may therefore be induced by the increasing phosphate load due to decreased renal phosphate excretion, or it may simply be due to decreased clearance of FGF23. Treatment with vitamin D analogs may further increase FGF23, although this can not be the only reason because elevated FGF23 levels is also observed in hemodialysis patients never treated with vitamin D or its analogs.90 PTH can stimulate FGF23 expression directly, or indirectly through an increase in 1,25-dihydroxyvitamin D.90-92 Calcium may also stimulate FGF23 expression although sparse knowledge of this mechanism is present at the moment.93

FGF23 is independently associated with mortality in incident and prevalent dialysis patients.94;95 Increased FGF23 is associated with left ventricular hypertrophy, kidney disease progression and vascular disease.96-98 Like the other factors in the mineral metabolism, it is unknown whether regulating FGF23 has any influence on morbidity and mortality

VITAMIN D TREATMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE

In order to replace the deficiency of 1,25-dihydroxyvitamin D, vitamin D compounds are widely used in patients with chronic kidney disease

Calcitriol (1α,25-dihydroxyvitamin D3) is a synthesised drug that corresponds to the endogenous active form of vitamin D. Alfacalcidol (1α-hydroxyvitamin D3) is classically considered a pro-hormone of 1α,25-dihydroxyvitamin D3. Alfacalcidol is converted into 1α,25-dihydroxyvitamin D3 after 25-hydroxylation in the liver.99

Increasing doses of vitamin D analogs are required to suppress SHPT with progressing CKD, probably because of a reduction in the VDR and the CaSR.9 This dose escalation is limited by increasing phosphate and calcium levels. New vitamin D analogs has been synthesised in order to achieve parathyroid hormone suppression without simultaneous hypercalcemia or hyperphos-

phatemia: doxercalciferol (1α-hydroxyvitamin D2) which is 25-hydroxylated in the liver to become 1,25-dihydroxyvitamin D2, paricalcitol (19-nor-1α,25-dihydroxyvitamin D2), maxacalcitol (22-oxa-1α,25-dihydroxyvitamin D3) and Falecalcitriol (26,27-F6-1,25-dihydroxyvitamin D2)

The native form of vitamin D; cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2), are increasingly used in daily nephrology practice. The presence of the wide distribution of the VDR100 and 1α-hydroxylase 101-103 in the body, makes a local synthesis of 1,25-dihydroxyvitamin D possible, and native vitamin D may be needed for paracrine or autocrine functions.

The active vitamin D analogs used in Denmark are alfacalcidol and paricalcitol. Alfacalcidol has been used in Denmark since 1974.104 Paricalcitol was introduced in Denmark in 2004. Both are primarily used because of the classical endocrine actions mediated through bone, intestine, kidney and parathyroid glands, in order to control the disturbances in mineral metabolism and prevent renal osteodystrophy. Whether there is any difference in the ability of alfacalcidol and paricalcitol to control the disturbances in the mineral metabolism in patients with chronic kidney disease are widely unknown, as the comparative data of these two analogs are sparse. In order to address this question we collaborated with a group of Danish nephrologists from different Danish departments to make an intervention study possible.105

Alfacalcidol
Alfacalcidol is a vitamin D3 hydroxylated at the 1α position. Alfacalcidol was synthesised from cholesterol in 1973 and found to be an easy and cheap way to produce an 1,25-dihydroxyvitamin D derivative.106 At first, alfacalcidol was used in order to increase the intestinal calcium absorption in patients with chronic kidney disease and thereby improve the skeletal abnormalities.106;107 Later, the direct suppressive effect of 1,25-dihydroxyvitamin D on parathyroid synthesis and secretion was discovered.108-110
A suppressive effect of alfacalcidol on hyperparathyroidism has been demonstrated in CKD 5D patients in controlled oral studies,111;112 and in uncontrolled long-term intravenous studies,113 and in CKD 3-5 patients in randomised placebo controlled studies of 11 weeks and 18 month.114;115 A concomitant calcium increase was observed in all these studies.
Alfacalcidol is classically considered as a prohormone to 1,25-dihydroxyvitamin D, which exerts its effects after 25-hydroxylation in the liver. However, comparative studies of alfacalcidol and calcitriol indicates that there may be a difference in their pharmacokinetics and pharmacodynamics.

In single dose studies, 4 µg doses of alfacalcidol and calcitriol had the same acute suppressive effect on PTH.116 This in spite of alfacalcidol leading to lower levels of 1,25-dihydroxyvitamin D3 , measured as area under curve (AUC) and maximal concentration (Cmax), than calcitriol. This may indicate an effect of alfacalcidol even before 25-hydroxylation.104 This is supported by in vitro studies showing equal suppression of PTH secretion from bovine parathyroid cells in response to alfacalcidol and 1,25-dihydroxyvitamin D.117 Indeed, a direct suppressive effect of alfacalcidol and doxercalciferol (1α-hydroxyvitamin D2) on PTH production in bovine parathyroid cells has been observed, and for doxercalciferol this was further explored and found to persist after blocking the local 25-hydroxylation. This 25-hydroxylation independent effect could probably be applied to alfacalcidol too.118

Opposite, in direct comparative studies of high dose (10µg) alfacalcidol and calcitriol, a higher potency of calcitriol was found, as an increased s-calcium and a significant greater decrease in

Table 1

Observational studies of the influence of vitamin D analogs on cardiovascular morbidity and mortality

	Population/Treatment	Design/Results
Teng et al. 2003 56	67,399 HD patients Paricalcitol vs. Calcitriol. US	**Baseline Cox models** **Mortality 16% lower with paricalcitol**
Shoji et al. 2004 57	242 HD patients Oral alfacalcidol vs. no treatment. Japan	**Baseline Cox models** **CVD mortality 71% lower in treated pt** **HR 0.287 (95% CI 0,127-0,649)** **Total mortality: no difference**
Teng et al. 2005 58	51,037 HD patients Calcitriol/paricalcitol vs. no treatment. US	**Time dependent Cox, marginal structural model.** **Increased survival in treated HR 0,80 (95% CI 0,76-0,839**
Tentori et al. 2006 59	7,731 HD patients Calcitriol/doxercalciferol/paricalcitol vs. no and each other. US non profit- dialysis	**Baseline and timedependent cox model.** **Increased mortality in untreated: HR 1.20 (95% CI 1.10-1.32).** **No difference between treatments in adjusted models**
Melamed et al. 2006 29	1,007 HD patients.Calcitriol vs. no treatment. US	**Baseline and time dependent Cox models** **Decreased all cause mortality in treated: HR 0.75 (95% CI 0.56-1.00)**
Kalantar-Zadeh et al. 2006 26 **Lee et al. 2007 60**	58,058 HD patientsParicalcitol vs. no treatmentUS 16,004 HD patients Calcitriol/alfacalcidol vs. no treatment. Latin America	**Baseline and time dependent cox models.** **Increased survival in paricalcitol treated**
Naves-Diaz et al. 2008 61	16,004 HD patients Calcitriol/alfacalcidol vs. no treatment. Latin America	**Time dependent Cox models.** **Decreased mortality in treated: HR 0.55 (95% CI 0.49-0.63)**
Kovesdy et al. 2008 62	520 CKD 3-5 male Calcitriol vs. no treatment. US	**Poisson Regression models** **Decreased mortality in treated RR: 0.35 (95% CI 0.23-0.54)**
Shoben et al. 2008 63	1,418 CKD 3-4 Calcitriol vs. no treatment. US	**Baseline dependent Cox model** **Increased survival in treated: HR 0.76 (95% CI 0.60-0.95)**
Tentori et al. 2008 64	38,066 HD patients Oral paricalcitol/calcitriol/doxercalciferol vs. no treatment. (Europe, Japan, North America, Australia, New Zealand)	**Baseline cox model no difference in survival.** **Departments with high versus low rate of vitamin D analog use. RR 0.99 (95% CI 0.94-1.04)** **Survival benefit in treated in timevarying cox models and marginal structural models**
Shinaberger et al. 2008 65	34,307 HD patientsParicalcitol vs. no treatment. US	**Baseline cox models.** **Higher paricalcitol/PTH ratio associated with lower mortality**
St. Peter et al. 2009 66	193,830 HD patientsCalcitriol/paricalcitol/doxercalciferol vs. no treatment. US	**Time-varying Cox model** **All-cause mortality decrease with increasing doses and shorter dialysis duration. No effect on cause specific mortality**
Sugiura et al. 2009 67	665 CKD 3-5 Alfacalcidol vs. no treatment. Japan	**Cox proportional analysis** **All-cause mortality no difference after adjustment. Decreased CVD events in treated.**
Jean G et al. 2010 68	648 HD patientsAlfacalcidol vs. no treatment. France	**Cox proportional hazard** **Survival increase in low dose disappeared after adjustment**

PTH.119 This could be due to the need of 25-hydroxylation of alfacalcidol, which delay the response. Supported by studies in osteoblasts from neonatal rats, where the nuclear uptake of 3H-alfacalcidol were found to be delayed and sustained compared to 3H-calcitriol.120

Long-term comparative studies of alfacalcidol and calcitriol have been performed in three small randomised clinical trials, with conflicting results. El-Rashaid et al.121 found an equal suppression of PTH during intravenous calcitriol and alfacalcidol, 3 µg weekly, in 20 hemodialysis patients, in a 3 month cross-over study. Similar changes in calcium, phosphate and 1,25-dihydroxyvitamin D levels were observed in both groups. The similar changes in 1,25-dihydroxyvitamin D and PTH supports the hypothesis that, alfacalcidol is a pro-drug to calcitriol. This was questioned in a recent study of intermittent oral alfacalcidol and calcitriol in Asian hemodialysis patients by Kiattisunthorn et

al..111 Twenty-four weeks of treatment induced equal PTH suppression, and no difference in calcium or phosphate increase. The final dose of alfacalcidol was 70% higher than the calcitriol dose. But the oral bioavailability of calcitriol is 140% higher than alfacalcidol in acute pharmacokinetic studies 116 and Kiattisunthorn et al. speculate that the lower maintenance dose could be due to a direct effect of alfacalcidol. It should be emphasised that levels of 1,25-dihydroxyvitamin D were not measured, and long-term pharmacokinetic studies demonstrated an increased AUC for oral alfacalcidol after 12 weeks daily treatment, probably because of an increased basal 1,25-dihydroxyvitamin D level.122

The third randomised study by Moe et al. compared alfacalcidol and calcitriol in five Canadian hemodialysis patients in a cross-over study. Six weeks of intervention with oral calcitriol suppressed PTH, whereas no change was observed during oral alfacalcidol treatment. The calcium and phosphate levels were un-

changed.123 The lack of effect in the alfacalcidol group was probably due to equal low oral dosing in both groups of 0.75 µg thrice weekly. Levels of 1,25 dihydroxyvitamin D was not measured

In a retrospective study published in Spanish, with an English abstract,124;125 21 hemodialysis patients were changed from intravenously calcitriol treatment into alfacalcidol treatment and followed for 15 month. The PTH increased after the conversion without any significant changes in s-calcium and with improved s-phosphate control. This may also be due to a too low dose of alfacalcidol, which was reported as 1.5 times the calcitriol dose.

Paricalcitol
Paricalcitol differs from calcitriol, as it has a D2 side chain and lacks the exocyclic C19. Paricalcitol was developed in order to posses a suppressive effect on PTH synthesis and parathyroid hyperplasia with less activity on bone and intestine, and thereby less elevated calcium and phosphate levels.
In uremic rats, paricalcitol suppressed PTH and PTH mRNA without significant changes in s-calcium or s-phosphate, whereas the calcitriol doses leading to the same degree of PTH suppression, at the same time induced hypercalcemia and hyperphosphatemia.126 In a following study in the uremic rat, paricalcitol was found to decrease the parathyroid gland growth, with no effect of calcitriol.127 However, a decrease in parathyroid size has been described in uremic rats, when treated with calcitriol.128

The efficacy and safety of intravenous paricalcitol was compared to placebo in three phase III studies. In 78 hemodialysis patients treatment by forced titration were given for 12 weeks after a 4 week long wash out period, and 68% of the paricalcitol treated patients experienced a decrease in PTH of more than 30%. Serum phosphate did not change significantly during the study, serum calcium increased significantly in the paricalcitol treated group although still inside the normal range.129 Episodes of hypercalcemia were associated with marked decreases in PTH.130 In a paediatric dialysis population, paricalcitol suppressed PTH more than placebo, without difference in changes of calcium, phosphate or calcium-phosphate product.131 Later oral paricalcitol was shown to decrease PTH, while calcium and phosphate were kept inside the clinical recommended level in CKD 3-5D patients.132;133

The long term efficacy and safety of intravenous paricalcitol was evaluated in 164 hemodialysis patients in an open label study with follow up for 13 months.134 In this population the mean PTH level reached the recommended level (100-300 pg/ml) after five month. The calcium and phosphate levels were kept inside the appropriate range

In order to address whether this apparently less hypercalcemic and hyperphosphatemic compound did present any differences to standard therapy in the US, paricalcitol was compared to calcitriol. A six fold greater dose of paricalcitol led to significantly less increase in phosphate and calcium levels, while the same degree of PTH suppression were achieved as after calcitriol, in acute intravenous administration in hemodialysis patients.135 During 32 weeks, paricalcitol and calcitriol were compared in 263 hemodialysis patients treated with escalating doses. Paricalcitol treated achieved a more rapid decrease in PTH. The mean PTH were lower at the end of study in the paricalcitol group, although no significant difference in the proportion of patients reaching >50% decrease in PTH was found. The paricalcitol treated group presented less episodes of persistent hypercalcemia and elevated Ca x P product 136. Calcitriol and paricalcitol were also compared

in a small randomized study of 25 hemodialysis patients with severe hyperparathyroidism (>50 pmol/ml). Unfortunately changes in PTH were not compared between groups, leading to a missing conclusion from these data.137 The changes in biochemical measurements were described in a retrospective study of 59 patients followed for 12 month before and after changing from calcitriol to paricalcitol. A decrease in PTH, calcium, phosphate, alkaline phosphatase and episodes of hypercalcemia and hyperphosphatemia was found. The observational design has several limitations and the presence of changes in phosphate binders were not reported.138
The mechanisms leading to lack of hypercalcemic and hyperphosphatemic properties of paricalcitol compared to calcitriol has not yet been fully explored.

In parathyroidectomized rats with dietary calcium and phosphorous restriction paricalcitol induced 10 times less increase in calcium and phosphate levels than calcitriol. At the same time only calcitriol induced an increase in renal urinary calcium levels. This points to a decreased bone mineral mobilization by paricalcitol.139 Furthermore, in mice paricalcitol stimulated anabolic bone formation more, and bone resorption less, compared to calcitriol.140

In rats with and without renal insufficiency, paricalcitol were 10 times less active stimulating intestinal calcium and phosphate absorption and paricalcitol was less potent in stimulating the expression of intestinal vitamin D dependent genes, CaT1, calbindin and PMCA1, involved in calcium transport.141;142 This may be explained by a diminished induction of the intestinal VDR by paricalcitol compared to calcitriol as shown in the uremic rat.127 The decrease in VDR may be caused by the simultaneous falling endogenous 1,25-dihydroxyvitamin D level, induced by an induction of 24-hydroxylase mRNA, which has been shown as a response to paricalcitol treatment in rat intestine.127 In a randomized cross-over study of 22 hemodialysis patients, the intestinal calcium absorption was measured by a single tracer method. In a 1:3 dosing of calcitriol:paricalcitol, paricalcitol induced a lower intestinal calcium absorption. However, the overall intestinal calcium absorption was low, and the authors suggest a general defect intestinal calcium absorption in this group of patients.143 This suggests that, the vitamin D induced hypercalcemia may be mediated by other mechanisms than increased intestinal absorption in hemodialysis patients. It could however also be a question of dosing
The pharmacokinetics of paricalcitol does not explain any differences compared to calcitriol.

Paricalcitol is found to have nearly the same vitamin D binding protein affinity, tissue distribution and circulating half life as 1,25-dihydroxyvitamin D.144;145 The affinity for VDR is 33% of the affinity of 1,25-dihydroxyvitamin D, which should not be enough to explain the observed differences.127;139;144

Comparison of alfacalcidol and paricalcitol
Alfacalcidol has not been compared to paricalcitol in a randomised study, before the present.

Until the present study an observational and two small switch studies comparing alfacalcidol and paricalcitol has been reported. Their information was the only available knowledge to guide the nephrologists, when choosing between the available vitamin D analogs in Denmark for treatment of the CKD patient

In the Swedish observational study, an unselected population of 92 hemodialysis patients was treated with paricalcitol and efficacy and safety was registered. Ninety-three% were former treated with alfacalcidol. A significant decrease in PTH was found

especially in the group with elevated PTH (>300pg/ml). Calcium levels increased significantly in the patients with elevated PTH, while phosphate levels were unchanged. It is unknown whether improved dose titration of alfacalcidol would have reached comparable results.146

Two small switch studies published as conference abstracts compared alfacalcidol and paricalcitol. In the first study six hemodialysis patients with uncontrolled hyperparathyroidism were treated with intravenous paricalcitol for 3 months and afterwards they were converted to alfacalcidol. The level of PTH declined significantly after 3 month of paricalcitol treatment compared to the level after 3 month of alfacalcidol treatment. The level of s-phosphate and s-calcium remained unchanged.147 We described an observational study of 20 hemodialysis patients with moderate-severe secondary hyperparathyroidism uncontrolled by alfacalcidol treatment. After a minimum of 18 month treatment with alfacalcidol they were converted to paricalcitol treatment and data was collected 18 month after treatment switch. Paricalcitol decreased iPTH significantly. This effect was probably mediated through a normalization of ionized s-calcium, as ionized s-calcium had decreased while iPTH increased during the alfacalcidol treatment. S-phosphate remained unchanged although still elevated during paricalcitol treatment.148 Both of these studies also lack the information of whether optimisation of alfacalcidol treatment had reached the same results.

These studies generates the hypothesis that paricalcitol may be superior to alfacalcidol concerning the control of disturbances in the mineral metabolism. However, the observational nature of these studies with lack of randomisation, comparison during the same time, and scheduled treatment makes them unable to answer whether such a difference exists.

AIM OF THE STUDY

In order to compare the vitamin D analogs available for treatment of secondary hyperparathyroidism in Denmark, a randomised cross-over multicenter trial was set up in a collaboration of eight Danish nephrology departments. The study design and methods are published in **Paper I**.105

The primary objective of this study was to evaluate the ability of paricalcitol and alfacalcidol to suppress secondary hyperparathyroidism in hemodialysis patients, while keeping phosphate and calcium inside the acceptable range. **Paper II** (accepted for publication in Kidney International)

In a substudy the arterial stiffness was assessed in order to address the influence of alfacalcidol and paricalcitol on this cardiovascular risk parameter. Data presented in this thesis

During the intervention study blood was frozen in a bank for later analysis. FGF23 entered the field as an important regulator of the phosphate metabolism and predictor of mortality while the study was running. The influence of alfacalcidol and paricalcitol on FGF23 was explored. **Paper III** (submitted)

METHODS
STUDY DESIGN

The design of the study is thoroughly described in paper I. It will be briefly described here and some aspects will be discussed.

Participants

Eligible patients represented the population of chronic hemodialysis patients, candidates for treatment with vitamin D analogs according to the present guidelines.48 Therefore an iPTH > 350 pg/ml, p-phosphate < 1.8mmol/l and p-ionised calcium < 1.25 mmol/l were inclusion criterions. A maximal dose of 1600 mg calcium-containing phosphate-binders a day was allowed.


Figure 1
Treatment periods and treatment arms

Intervention

86 patients were randomised into two treatment arms of the cross-over study after a minimum of 6 weeks wash out or directly if former untreated (4 patients) **Figure 1**

During 16 weeks of treatment the dose of alfacalcidol and paricalcitol was increased 50% by forced titration every second week. The dose was increased until PTH was suppressed below 150 pg/ml, or p-phosphate increased above 1.80 mmol/l, or p-ionised calcium increased above 1.30 mmol/l.
The forced titration was chosen in order to reach the maximal possible suppression of the hyperparathyroidism, while keeping the calcium level and phosphate level inside the target range. The intervention period was 16 weeks in this study based on earlier interventional studies showing a plateau of PTH at this time when treated with paricalcitol149 or alfacalcidol.150 However, in a study of dialysis patients with PTH >600 pg/ml and resistance to calcitriol, switching to paricalcitol decreased PTH levels after 6 month and even further after 12 and 16 month.151 It cannot be rejected that, a further decrease in PTH levels would be present if the intervention was prolonged.
The initial dose ratio was alfacalcidol:paricalcitol in 1:3. According to a conversion study, where hemodialysis patients with PTH levels higher than 600 pg/ml during calcitriol treatment had the smoothest PTH control without increase in calcium after switch to paricalcitol in 1:3 dose ratio.151 It may be questioned whether enough calcitriol was given prior to conversion, as this was not reported. However, this was the recommended conversion ratio, when our study was designed.

This assumes an equal potency of alfacalcidol and calcitriol. An acute study of intravenously 4 µg116 and long-term study with maintenance dose 1 µg iv thrice weekly121 found equal PTH suppression by alfacalcidol and calcitriol, with no difference in calcium and phosphate levels. This supports an equal potency of alfacalcidol and calcitriol.

The discussion of the conversion ratio is omitted by the forced titration where dosages were increased until the treatment goal was reached.

Blinding and randomisation

The study was un-blinded. The many different doses (29 possible doses) made it unreachable to blind the study medication. The endpoints was laboratory data and therefore not prone to bias.

But there could be a bias concerning concomitant treatment in an un-blinded design. Obvious differences could be: Different use of phosphate-binders, this was registered. Different degree of dietary advice and dialysis dosage, this was not registered. Calcium in the dialysate, this was fixed at 1.25 mmol/l. Calcimimetics usage, which was not allowed.

The patients were randomised by concealed allocation using opaque sealed envelopes that was opened consecutively. Randomisation in blocks of ten 1:1, secured an equal distribution at each centre.

Outcome

The primary end point was the proportion of patients reaching ≥30% reduction in PTH from baseline until the last four weeks of treatment. This endpoint has been used in other studies evaluating the efficacy of vitamin D analogs.129;131;133;135;152;153 This dichotomous outcome reduces the information from the present data. Therefore the numerical changes and the percentage changes were also compared. Furthermore, the proportion reaching a suppression of iPTH below 300 pg/ml, which were the target in the K/DOQI guidelines, was analysed.47

The data were analysed with baseline levels as covariates and there was significant treatment x baseline interaction. Therefore the data was also described in patients with high baseline; PTH >600 pg/ml and low baseline; PTH <600 pg/ml. This separation of data is interesting as the acceptance of an even higher PTH level 2-9 times the upper normal limit is present in the current KDIGO guidelines, calling for a less aggressive dosing approach in the patients with PTH <600 pg/ml.2 The wider PTH interval is established because PTH in recent studies is not as predictive of low and high bone turnover as in older studies.154 Perhaps because of different PTH assays, as used in the present study or because of the influence from new treatment modalities. Furthermore, the epidemiological studies points to higher, although varying, inflection points above which PTH is associated with decreased survival.33

Sample size

117 patients were planned to be included based on former studies, where the proportion of patients achieving ≥ 30% reduction in PTH in the last four weeks of the treatment period was 50% during alfacalcidol treatment and 68% during paricalcitol treatment.129;150 Reaching a power of 80% to detect a significant difference (P = 0.05, McNemars test). The power calculation was supervised by Eastern Danish Research Forum for Health Sciences.

Patients were recruited for 30 month. The trial was stopped before reaching the 117 patients because of lack of eligible patients. No interim analysis was performed, and the centres were prompted to do a final effort to recruit participants before the final date of inclusion. A number of 86 patients were included. Because of a period effect in the PTH level, and drop outs, only data from 80 patients fulfilling the first treatment period were analysed for the effect on hyperparathyroidism. The power to detect a difference in PTH reduction of 10%, 20% and 30% between alfacalcidol and paricalcitol were calculated for the achieved sample size.

In the present trial, the alfacalcidol group (n = 38) had an average decrease in PTH (SD) 53.1% (33.2) and the paricalcitol group (n = 42) had an average decrease in PTH (SD) 63.8% (23.1). A two-tail test (α = 0.05) gives a power of 33% to detect a 10% difference, a power of 86% to detect a 20% difference and a power of 99.6 % to detect a 30% difference between groups.

In order to describe the ability of the present study to detect any differences in changes of calcium and phosphate between alfacalcidol and paricalcitol a calculation of the power to detect differences of 5% and 10% were performed. These differences did not give a power of 80% concerning the phosphate changes, and the power to detect a difference of 20% was also determined for phosphate changes.

A calcium increase of 5% and 10% is detected with a power of 77.5% and 99.9% respectively, based on the observed increase in ionised calcium in alfacalcidol 10.4% (9.0) and paricalcitol 11.1% (7.2) in the present study.

A phosphate increase of 5%, 10% and 20% is detected with a power of 11%, 28% and 79% respectively, based on the observed increase in phosphate levels of 15.1% (29.2) in alfacalcidol treated and 13.4% (34.8) in paricalcitol treated in the present study.

BIOCHEMICAL MEASUREMENTS

All blood samples were drawn from the line of the dialyzer prior to hemodialysis

Parathyroid hormone

The PTH 1-84 is stored in secretory granules together with inactive fragments before secretion. The half-life of PTH 1-84 is 2-4 minutes. Both before and after secretion PTH 1-84 are cleaved into C-terminal, mid-region and N-terminal fragments, which are metabolised in the liver and the kidney. Therefore both PTH 1-84 and PTH fragments are circulating in the blood

The level of parathyroid hormone is measured by immunoassays. Three generations of PTH assays exist.

The first generation assays were radioimmunoassays and consisted of an antibody directed against one sequence of PTH, most of them against the C-terminal region. These assays measured also the circulating C-terminal fragments. The C-terminal fragments have a longer half life than PTH 1-84, are eliminated by the kidney and accumulate in CKD patients.155 Therefore, the first generation assay measured high levels of PTH in CKD and are no longer used for clinical purposes.

The analysis methods most widely used to measure PTH is the second generation methods, also called the intact-PTH assays. It is two-site sandwich immunoassays where a captured antibody directed against the N-terminal region of PTH and a labelled antibody directed against the C-terminal region of PTH binds to PTH 1-84. However, these assays also detect large C-terminal fragments, a mixture of four PTH fragments similar in size to PTH 7-84.156

The third generation assays are also two-site immunoassays, but detects only the full length PTH 1-84 (whole-PTH or total-PTH) with a C-terminal antibody directed against the very first amino acids 1-4. However, a new PTH, the amino-PTH (N-PTH) is recently discovered. N-PTH differs from PTH 1-84 in the 15-20 region, perhaps by a phosphorylated serine residue. N-PTH are measured by the third generation and some of the second generations methods.157

The K/DOQI guidelines were the clinical guidelines when writing the primary protocol of the study and recommended to maintain the iPTH inside the interval of 150-300 pg/ml using a second generation assay.47 This was derived from studies that compared histomorphometric data in dialysis patients with iPTH measurements by a second generation assay, the Allegro assay.15 The Allegro assay is not currently available. In order to evaluate the other available PTH assays, a study compared the Allegro assay with 14 other commercial assays, including the Elecsys PTH (used

by four study sites) and Immulite 2000-intact PTH (used by 3 study sites), and found a difference in iPTH by a factor >2.5 between the assays.158 As the different immunoassays are generally highly correlated Souberbielle et al has recently proposed a correction factor for some of the common used measurement kids, including the methods used in this study.159

The reason for the intermethod discrepancies may be found in the mixture of different molecules that make up the circulating PTH. C-terminal fragments are not detected by the second generation assays, but N-terminal truncated PTH fragments and amino-PTH (N-PTH) are both detected in different degrees by the second generation assays.12;160 Furthermore, there is no international standard against which the assays are calibrated.

The PTH results are also under influence from other factors. PTH differs between plasma and serum, and depends on how the samples are handled preanalytically.161 In addition, PTH fluctuates in the individual as it is secreted from the parathyroid glands in seasonal, circadian and ultradian pulsatile rhythm.162

The many factors influencing the result of a PTH measurement calls for standardization of the sample collection, processing and use of assay in every day clinic. As the third generation assay has not been shown to improve the predictive value of bone disease, and are not widely spread at the moment, the current KDIGO guidelines recommend using the second generation assay.2

The level of parathyroid hormone was measured by the participating sites standard routine analysis. Three different analysis methods were used. **Table 2**. The same analysis method was used in each site during the study. The block randomisation and cross-over design eliminates the concerns regarding different types of assays and sample handling a each site

Calcium
Calcium was measured consecutively at the local laboratory by ion-selective electrodes. The ionized calcium is the fraction of circulating calcium important for physiologic processes. As it is dependent on pH, we measured ionized p-calcium corrected to pH 7.4.

Phosphate
Phosphate was measured consecutively at the local laboratories. The ammonium-molybdat method was applied. Phosphate reacts with ammonium-molybdat to form phosphomolybdat in the presence of sulphuric acid. This can be measured by colorimetric method

Alkaline phosphatase
Alkaline phosphatase was measured at the local laboratories at the participating centres by colorimetric analysis. P-nitrophenylphosphate is separated by alkaline phosphatase into phosphate and p-nitrophenol in the presence of zinc and magnesium ions. The light absorption of p-nitrophenol is direct proportional with the activity of alkaline phosphatase.

25 hydroxyvitamin D
The level of 25 hydroxyvitamin D was measured at the laboratory of each participating centre. This led to analysis performed by four different methods. Two types of automated immunoassay [trial centre according to table 2]: Diasorin Liaison Total [04, 05, 07], IDS iSYS [10]. Two direct detection methods: HPLC [08], LC-MS/MS [03, 06, 09].

The results from different assays at different laboratories has been shown to differ up to 38%.163 Until recently a lack of a

common calibrator has hindered the standardization of the available methods. For the immunoassays over or under-estimation of vitamin D2, cross-reactivity with other vitamin D metabolites and matrix effects may influence on the result.164

The same method was used for the whole period at each trial centre and the level of 25 hydroxyvitamin D were considered as the sum of vitamin D2 and vitamin D3 where both were stated.

1,25 dihydroxyvitamin D
The 1,25-dihydroxyvitamin D level was measured by a complete assay with monoclonal immunoextraction followed by quantitation by radioimmunoassay. AA-54F2 IDS Ltd, UK (normal range 51-177 pmol/l). This analysis was performed consecutively in included patients at one centre [05].

FGF23
FGF23 was measured in blood serum samples stored in a freezer at the beginning and at the end of each treatment period. Samples from 57 participants were available for analysis.
There are currently two types of FGF23 assays. The C-terminal assay recognizes two epitopes in the C-terminal end of FGF23 and capture both intact FGF23 and its C-terminal fragment.165 In contrast, the intact assay binds two epitopes placed on each side of the cleavage site166 and therefore only measures the intact FGF23 molecule. Several studies have shown high correlation between these assays in CKD and at least in peritoneal dialysis patients all circulating FGF23 is intact.166-169 At the moment both assays seems appropriate for use in CKD. The intact assay was used in the present study

PULSE-WAVE PARAMETERS

Pulse wave velocity and pulse wave morphology was assessed at the beginning and at the end of each study period.

The measurement was performed by applanation tonometry. A pencil shaped high-fidelity micromanometer registers the intra-arterial pulse-wave, when applied over a peripheral artery (a. radialis, a. carotis and a. femoralis).

Ten seconds record of the arterial pressure in a. radialis was transformed to a central aortic wave form. This was done by the general transfer function in a validated software program; SphygmoCor® (version 8.0, AtCor Medical, Sydney, Australia). The measurements were calibrated by the brachial blood pressure. From the central blood pressure curve the augmentation index (AIx) was calculated by the software. AIx is a measurement of the pulse wave amplification due to peripheral reflexion of the pulse wave. AIx is calculated as the difference between the first and second systolic peak as a percentage of the central pulse pressure (difference between central systolic and diastolic pressure).

The measurement of aortic pulse wave velocity was done by measurement of pressure wave forms in a. carotis and a. femoralis and a simultaneous electrocardiogram (ECG). The transit time was calculated as the time between the R-spike in the ECG and the arrival of the foot of the pulse wave (intersecting tangent) at the peripheral recording sites. The travel distance was measured by subtracting the carotid-suprasternal notch distance from the suprasternal notch-femoral distance.170

All measurements were done in duplicate. The sphygmocor software provides a quality control of the recorded pressure

	generation	Epitope of coated Ab	Epitope of labelled Ab	tracer	Reference range	Trial centre	Material P=plasma S=serum
Elecsys 2010 (ROCHE)	2nd	26-32	37-42	Ruthenium	1.6-6.9 nmol/ml	03,06,07,09	P,P,P,P
Immulite 2000 (DPC)	2nd	44-84	1-34	Alkaline phosphatase	1.3-6.8 nmol/ml	04,08,10	S,S,P
Architect (Abbott)	2nd	39-84	1-34	Acridinium	15-68,3 pg/ml	05	P

Tabel 2
Parathyroid hormone assays used in the participating centres
Trial centre: Holbæk: 03, Holstebro: 04, Roskilde: 05, Viborg: 06, Aalborg: 07, Odense: 08, Skejby: 09, Esbjerg: 10. (Trial centre 01 and 02 did not recruit any participants). Reference ranges from Product Summary. The assay results reported in SI units were converted into metric units according to K/DOQI guidelines 47: pmol/ml = pg/ml x 0.11

waveforms. If these control criteria's was not met the measurement was discarded and replaced by a new measurement.171 A standard operating procedure was thoroughly described, in order to standardize the assessment in the three participating centres [05, 07, 08] and the assessors were trained at each participating site.

Examinations were performed before hemodialysis on the first day of dialysis in the week. The measurements were performed after ten minutes rest in a calm environment and at a constant room temperature. The participants were not allowed to speak or sleep during the examination. The patient was not allowed to eat, drink or smoke three hours before and consume any alcoholic beverage ten hours before the examination. It is well known that the examination conditions influences the hemodynamic parameters.172 Therefore, the measurements were performed according to the present guidelines.173

STATISTICS

Continuous data are described as mean (SD), and for differences mean (SEM), if normal distributed, and median (range) if not normal distributed and for very small groups. Paired t-test for normal distributed and Wilcoxon test for not normal distributed data were used for comparing changes before and after treatment within groups. Unpaired t-test for normal distributed and Mann-Whitney test for not normal distributed data compared changes between groups. Proportions were compared by Fischer's Exact Test. All tests were two-sided. A P-value <0.05 was considered statistical significant

Correlations were described by Pearson correlation coefficient. General linear models and multiple logistic regression models were used for the analyses of differences between effects of treatment by alfacalcidol and paricalcitol. AUC for receiver operated curves was compared with the null-hypothesis: AUC = 0.50

Statistical analysis was performed using SPSS® Statistics 17.0 (SPSS Inc., Chicago, IL) software and SAS 9.1 (SAS Institute Inc., Cary, BC, USA)

The presented studies are in compliance with the Helsinki Declaration of 1975, revised 1983, and approved by the Danish National Committee on Biomedical Research Ethics (SJ-27), the Danish Medicines Agency (EudraCT: 2006-005981-37), Danish Data Protection Agency (2007-41-0503) and registered in ClinicalTrials.gov (NCT004695)

RESULTS AND DISCUSSION
STUDY POPULATION

The randomised population was a representative cohort of the Danish dialysis population, evenly distributed across renal diagnosis. Diabetes was present in 17% of the patients compared to 22% in incident Danish patients with end stage renal disease.1 A high proportion of males; 64% corresponds to the proportion reported at dialysis initiation.174 The mean age of the studied patients was 64.5 years (SD 14.5) and the median time of dialysis was 37 month (range 3-262 month) at randomisation, this corresponds to a mean age in the Danish hemodialysis population of 64.7 years (SD 14.9) at the first of January 2011 (unpublished data, personal communication by James Heaf MD DMSc, Danish Nephrology Registry)

The study population may be in better condition than the overall hemodialysis population, as they had a slightly higher haemoglobin 7.31mM (SD 0.76) vs. 7.19 mM (SD 2.27) and albumin 40.2 g/l (SD 3.7) vs. 38.8 g/l (SD 4.8).1 Not surprising, as the patients were excluded if the expected survival was less than 12 month

SUPPRESSION OF SECONDARY HYPERPARATHYROIDISM

The analysis of the cross-over data for the percent changes in PTH, revealed a significant period effect (t = -3.946; P <0.001). No treatment-period interaction was found (t = 1.297; P = 0.199). The wash out interval between period 1 and 2 was insufficient. Baseline PTH in period 1 (552 pg/ml (SD 202)) was higher than period 2 (453 pg/ml (SD 249)); (P = 0.01). PTH levels before and after second wash out period was significantly correlated (r = 0.398; P = 0.001). A more pronounced suppression of PTH after treatment period 1 (219 pg/ml (SD 187)), than in the everyday clinic (P <0.001) illustrated by PTH before wash out period 1 (317 pg/ml (SD 155)) probably prevented the PTH increase during the second wash out period. A longer wash out period would be recommended for future studies. The half life of 1,25-dihydroxyvitamin D (assumed to reflect the half life of alfacalcidol) is 36 hours and paricalcitol 13-30 hours,116;144 therefore, the period effect is not mediated through a direct vitamin D analog effect but a prolonged biologic effect. A possible mechanism may be an upregulation of the vitamin D receptor175;176 or the calcium sensing receptor177 by vitamin D analogs withholding the PTH suppression by increased sensibility to endogenous vitamin D and calcium.

Because of the period effect, the cross-over data were not accessible for further analysis.

Both vitamin D analogs suppressed secondary hyperparathyroidism significantly during both treatment periods. We could not detect any statistically significant difference in % changes between groups, and there were not any statistically significant difference in the proportion of patients reaching a 30% reduction in PTH. **Table 3 and 4**.

Analysis of data from period 2 confirmed the data from period 1. As described this study should have enough power to detect a difference of 20% in PTH reduction between groups. A larger sample size may have detected a significant difference between groups, but probably of less than 20% PTH reduction.

	Period 1		Mean difference	Period 2		Mean difference
	Alfacalcidol (n=38)	Paricalcitol (n=42)	% ±SEM (unpaired t-test)	Alfacalcidol (n=34)	Paricalcitol (n=37)	% ±SEM (unpaired t-test)
% iPTH change ±SEM	-53.1 ±5.4	-63.8 ±3.6	10.7 ±6.5 (P=0.102)	-31.9 ±7.1	-37.0 ±6.2	5.0 ±9.4 (P=0.591)

Tabel 3
Changes in PTH during each period of alfacalcidol and paricalcitol treatment

	Period 1		P-value	Period 2		P-value
	Alfacalcidol (n=38)	Paricalcitol (n=42)	Fisher's Exact Test	Alfacalcidol (n=34)	Paricalcitol (n=37)	Fisher's Exact Test
≥30% iPTH supp.	31(82%)	39(93%)	0.180	20(59%)	25(68%)	0.471
iPTH<300pg/ml and phosphate<1.8mmol/l and ionised calcium<1.30mmol/l	7(18%)	13(31%)	0.301	10(29%)	15(41%)	0.456

Tabel 4
Number of patients reaching treatment goal during each period of alfacalcidol and paricalcitol treatment

CHANGES IN CALCIUM AND PHOSPHATE LEVELS

The overall equal PTH response was accompanied by equal % changes in calcium (P = 0.758) and phosphate (P = 0.819). Both groups increased ionised calcium (alfacalcidol: 9.3% (SEM 1.5); P <0.001 and paricalcitol: 9.9% (SEM 1.1); P <0.001) and phosphate (alfacalcidol: 15.1% (SEM 4.7); P = 0.028 and paricalcitol: 13.4% (SEM 5.4); P = 0.023). Mean ionised calcium increased just above the recommended target range (≤1.25 mmol/l) in both groups (1.26 mmol/l (SD 0.09)). However, according to the protocol, the upper limit for ionised calcium was 1.35 mmol/l in order to leave room for dose adjustment. Phosphate final levels were kept inside recommended target range (<1.80 mmol/l) in both groups: Alfacalcidol 1.67 mmol/l (SD 0.32 mmol/l), and paricalcitol 1.58 mmol/l (SD 0.34 mmol/l)). There were no differences in incidence of hypercalcemic and hyperphosphatemic episodes.
These results points to an equal ability of alfacalcidol and paricalcitol to control secondary hyperparathyroidism, with no difference in their adverse effects on calcium and phosphate levels.

We did not find any major differences in phosphate binder use, except for an increased prevalence of decreased sevelamer usage in the alfacalcidol group, which could disguise a lower phosphate level in the alfacalcidol group. Calcimimetics were not allowed. Dialysate calcium concentration was fixed at 1.25 mmol/l. The dialysis dose was only measured by urea reduction rate, where no difference in changes was present, and dietary intervention was not assessed. Dialysis dose and dietary intervention could influence the present results, as the study was open label.

Alfacalcidol is classically considered a pro-drug to calcitriol activated by 25-hydroxylation in the liver.[99] On this background, the present study was expected to show results similar to the study by Sprague et al.[149] comparing calcitriol and paricalcitol in north-American-European hemodialysis patients (n = 263). The proportion of subjects reaching a PTH suppression of 50% were analysed by Sprague et al., and like in the present study, no difference between groups were found.

A reduced incidence of hypercalcemia and/or elevated Ca x P for at least two consecutive blood draws and a reduced incidence of hypercalcemia for two blood draws and/or Ca x P for four blood draws were found in the paricalcitol treated group by Spra-

gue et al. Analysing our data for the same composite end points revealed no difference between groups **Table 5**.

This difference may be due to a type 2 error in the present study (failing to reject the null hypothesis, where a difference does exist), with fewer participants than in the study by Sprague et al., and half the interventional time period. It may be due to a type 1 error (rejecting the null hypothesis, when it is true) when analysing this composite end point by Sprague et al. Finally, it may be due to a difference in the effect of alfacalcidol and calcitriol, which is a possibility, as discussed in section 1.2.1.

As demonstrated in Table 4 more than 60% did not reach target concerning the combined end point of ionised calcium, phosphate and PTH after 16 weeks. Elevated calcium and PTH coexisted in 55% of the patients. This could probably be improved by additional treatment with calcimimetics which were not allowed in the present study.[178;179].

End point	Number (%) of patients		Fisher's Exact Test
	Alfacalcidol N=38	Paricalcitol N=42	P-value
Ionised calcium>1.30mmol/l and/or Ca X P ≥ 2.3mmol²/l² for at least two consecutive blood draws	23 (61%)	26 (62%)	P=1.000
Ionised calcium>1.30mmol/l for at least two consecutive blood draws and/or Ca X P ≥ 2.3mmol²/l² for at least four consecutive blood draws	14 (37%)	16 (38%)	P=1.000

Tabel 5
Number of patients with prolonged hypercalcemia or elevated Ca x P product during alfacalcidol or paricalcitol treatment in period 1.

RESPONSE TO VITAMIN D ANALOGS ACCORDING TO SEVERITY OF HYPERPARATHYROIDISM

The mean PTH during the last four weeks of treatment was analysed with baseline PTH as covariate and a significant baseline PTH x treatment interaction was found (P = 0.012). Which means, the treatment response depended on baseline PTH in the paricalcitol group, whereas alfacalcidol suppressed PTH across all baseline PTH values. This interaction was also found for numerical changes in PTH (P = 0.012), percentage changes of PTH (P = 0.036) as for number of patients reaching a 30% decrease in PTH (P = 0.047). Mean PTH during the last four weeks of period 2 were analysed in order to describe the reproducibility of this interaction. The same tendency was found, although not statistically significant (P = 0.10). However, as there were only 71 patients in this analysis a decreased power could explain the lack of significance.

The differentiated paricalcitol response is in accordance with a switch study from ordinary calcitriol to scheduled paricalcitol for 6 to 12 month in hemodialysis patients with SHPT. The baseline PTH level and size of ultrasound examined parathyroid glands were independently associated with response to paricalcitol treatment. The patients with the largest parathyroid glands and highest PTH responded least to paricalcitol treatment.[180]. Opposite, Llach et al.[151] converted hemodialysis patients with

Figure 2
iPTH and ionised calcium changes during period 1 in patients with baseline iPTH >600 pg/ml.§; unpaired t-test, P <0.05


Figure 3
iPTH and phosphate changes during period 1 in patients with baseline iPTH>600pg/ml.§; unpaired t-test, P<0.05.

calcitriol resistant hyperparathyroidism to scheduled paricalcitol treatment. A significant PTH decrease was found in both moderate (600 pg/ml < PTH > 800 pg/ml) and severe (PTH >800 pg/ml) hyperparathyroidism. In addition, Coyne et al.132 showed a consistent effect of oral paricalcitol across baseline PTH severity in CKD stage 3-4 patients in a placebo controlled study.

In the present study, the differentiated PTH response to paricalcitol across baseline PTH levels may be largely due to the pronounced suppression of PTH at the low baseline levels. Actually 48% of the paricalcitol treated and 29% of the alfacalcidol treated patients reached a PTH level less than 150 pg/ml (P = 0.110). The concern about increased risk of adynamic bone disease and increased mortality at low PTH levels would make the clinician keep the PTH above this level.26;33;44;181 It could be speculated that this interaction was not found if dosing schedule had kept the desired PTH between 150-300 pg/ml.

The observed difference in the effect of alfacalcidol and paricalcitol on PTH could be due to differences in calcium levels. We did not find any statistically significant difference between the calcium levels in the alfacalcidol group compared to the parical-

citol group, when groups were separated according to baseline PTH. Although, a tendency towards a higher ionised calcium was observed in the alfacalcidol treated patients with high baseline PTH. **Figure 2**

Increased phosphate stimulates PTH secretion by binding calcium, thereby decreasing calcium, and by stabilising PTH mRNA.182 The presence of a phosphate receptor has not been demonstrated in human at the moment. The changes in PTH and phosphate in patients with high baseline PTH is presented in **Figure 3**. Except from the final visit, an inverse relation between PTH and phosphate appears, reflecting the vitamin D induced phosphate increase, concomitant with the PTH suppression, overruling the physiologic phosphate-PTH regulation.

Only some of the possible differences in the direct effect of alfacalcidol and paricalcitol on the parathyroid gland have been explored. Alfacalcidol binds to the vitamin D receptor, with only 0.4% of the affinity of calcitriol.183 The affinity for paricalcitol is 33% of calcitriol.127 A direct suppressive effect of alfacalcidol and doxercalciferol (1α-hydroxyvitamin D2) on PTH production in bovine parathyroid cells has been observed, and for doxercalciferol this was further explored and found to persist after blocking the local 1α-hydroxylase.118 Given the low affinity for the VDR a suppressive mechanism by alfacalcidol may be possible if alfacalcidol is accumulated intracellular in the parathyroid cells. This accumulation is possible indeed as, paricalcitol has the same affinity for vitamin D binding protein (VDBP) as calcitriol, whereas alfacalcidol has a low affinity for VDBP, and alfacalcidol may therefore be rapidly taken up by peripheral tissues, including the parathyroid gland, before 25 hydroxylation by the liver.145 Another mechanism was proposed when Panda et al.184 demonstrated a suppressive effect of cholecalciferol on parathyroid hyperplasia in VDR null mice, whereas parathyroid glands enlarged in VDR null and 1α-hydroxylase null mice. This argues for the presence of a non-VDR receptor which could theoretically be activated by 1α-hydroxylated vitamin D lacking the 25 hydroxylation, such as alfacalcidol. Alfacalcidol and paricalcitol may induce different conformational changes in VDR when binding, differ in their interaction with co-repressor and co-activators required for VDR function,185 differ in their binding to intracellular proteins (i.e. Hsc-70, Bag-1) and differ in their induction of catabolic enzymes, i.e. 24-hydroxylase, affecting the local metabolism of active vitamin D.145 Vitamin D may induce rapid non-genomic responses through interaction with the cell membrane. The identity of a vitamin D membrane receptor is debated,7 and the relevance of the rapid response are not clarified, but may be a mediator of differentiated effects of the vitamin D analogs.145

TIME UNTIL SUPPRESSION OF SECONDARY HYPERPARATHYROIDISM

Both in the first period of the cross-over population (n = 71) and when comparing the groups going through period 1 (n = 80), it was found that paricalcitol decreased PTH faster than alfacalcidol and reached a 30% reduction (P = 0.034) or a PTH level beneath 300 pg/ml (P = 0.011), four and six weeks before the alfacalcidol treated patients. This difference was not found in the second period of the cross-over study, probably because the baseline level (week 28) was lower than the baseline level in the first period (week 6). The difference could be based on not equipotent dosing during titration. It is unknown whether a difference of four to six weeks before reaching the goal has any clinical importance for the long-term prognosis regarding bone fracture, and the cardiovascular disease risk apparently associated with ele-

vated PTH.[24;65;186] In SHPT the parathyroid cells proliferate, initially diffuse polyclonally hyperplasia, turning into nodular clonal proliferation in long standing, severe hyperparathyroidism.[187] In the clonal stage the VDR density is decreased[188] and responds less well to vitamin D treatment.[189] Early administration of calcitriol prevents the development of hyperplasia, whereas treatment of existing hyperplasia can not reverse the condition in uremic rats.[128] Whether a rapid reduction in SHPT is important in preventing further progression of the parathyroid hyperplasia, is unknown.

CHANGES IN PULSE WAVE VELOCITY AND MORPHOLOGY

Pulse wave velocity (PWV) and augmentation index (Aix) are both strong predictors of cardiovascular mortality in hemodialysis patients.[190;191] These are related to arterial calcification estimated by ultrasound in hemodialysis patients,[192] and the presence of coronary artery calcification in coronary angiography in CKD patients.[193]

Levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in adult hemodialysis patients and levels of 1,25-dihydroxyvitamin D in adult CKD 1-5 patients are negatively correlated with pulse wave velocity.[194;195] Aix is negatively correlated with 1,25-dihydroxyvitamin D in CKD 2-4 patients.[196] In children on dialysis no relation between PWV and levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D was found. Meanwhile a U-shaped relation between 1,25-dihydroxyvitamin D, and arterial thickness and cardiac calcification was found in the same study.[197] These abnormalities probably precede changes in PWV and Aix. Therefore it seems possible that, vitamin D or its analogs may influence on PWV and Aix

In order to participate in the exploration of a possible improved cardiovascular risk profile by vitamin D analogs, we initiated a substudy where aortic PWV and Aix was measured at the beginning and at the end of treatment. The substudy was planned to include 30 patients based on recently published data showing that 10 patients in each intervention-group should be enough to detect a difference in 1 m/s in aortic PWV, and 3 patients in each group to detect a difference in Aix of 10%, with a significance level of 5% and a power of 80%.[198]

Unfortunately, only ten patients completed the first treatment period (alfacalcidol=3; paricalcitol=7) and six patients completed both treatment periods (alfacalcidol=2; paricalcitol=4). There was no overall significant changes in Aix or PWV when comparing baseline with final value for all vitamin D analog treated (Wilcoxon signed rank test). The changes in each group during period 1 are shown in **Table 6**.

A statistical significant difference in % changes in PWV was found on the background of an increase in the alfacalcidol treated group and a decrease in the paricalcitol treated group.

Although the differences between treatments in PWV are interesting it is only hypothesis generating because of sparse data. It has been shown that patients with calcification progress over time, whereas patients without calcification are less prone to progress.[199] Although no statistical significant difference was found in baseline PWV, the patients in the alfacalcidol-group

	Alfacalcidol n=3 median (range)		Paricalcitol n=7 median (range)		% changes during treatment (SE)		
	Before VDRA	After VDRA	Before VDRA	After VDRA	Alfacalcidol	Paricalcitol	Mann-Whitney test (n.s when p≥0.05)
Brachial Psys (mmHg)	140 (86)	125 (88)	150 (61)	145 (83)	-5.1 (8.1)	1.1 (5.5)	n.s
Brachial Pdia (mmHg)	80 (21)	75 (10)	78 (42)	77 (53)	2.8 (11.0)	-4.2 (5.0)	n.s
Brachial PP (mmHg)	58 (67)	55 (83)	74 (29)	78 (50)	5.7 (6.4)	1.9 (8.4)	n.s
Central Psys (mmHg)	124 (82)	106 (83)	145 (61)	138 (77)	-6.3 (10.8)	-3.0 (5.4)	n.s
Central Pdia (mmHg)	81 (21)	77 (9)	80 (42)	79 (51)	-0.7 (10.5)	5.9 (5.2)	n.s
Central PP (mmHg)	41 (64)	36 (80)	68 (29)	62 (45)	-8.9 (10.7)	1.9 (9.7)	n.s
Tr (ms)	141 (10)	140 (1)	137 (27)	145 (20)	-3.9 (3.0)	4.0 (2.2)	n.s
Aortic PWV (m/s)	17.2 (6.7)	21.0 (1.0)	12.5 (6.9)	12.1 (7.5)*	17.6 (2.0)	-7.1 (4.5)	p=0.04
Aix@HR75 (%)	22.0 (10.0)*	31.0 (30.5)	34.5 (13.0)	26.5 (14.0)	14.0 (36.7)	-10.1 (6.1)	n.s
P-ionized calcium (mmol/l)	1.13 (0.18)	1.28 (0.21)	1.16 (0.22)	1.28 (0.42)≈	7.6 (3.7)	9.4 (3.9)	n.s
P-phosphate (mmol/l)	1.58 (0.20)	2.02 (0.50)	1.43 (0.80)	1.70 (0.70)	24.5 (5.2)	10.6 (6.9)	n.s
P-iPTH (ng/l)	1035 (714)	201 (361)	465 (379)	118 (215)≈	-62.5 (13.3)	-71.0 (4.6)	n.s

Tabel 6
Changes in hemodynamic parameters and mineral metabolism during period 1 in the subgroup where pulse wave morphology and pulse wave velocity were measured. Comparison between groups. Mann-Whitney test; *, p<0.05
Comparison within groups. Wilcoxon signed rank test; ¤, p<0.05
PP: Pulse pressure, Tr: Time to reflection, PWV: Pulse wave velocity, Aix@HR75: Augmentation index adjusted to heart rate 75

tended to start at a higher level of PWV and may be prone to progression.

The effect of vitamin D or its analogs on PWV and Aix has not been explored in CKD patients in other interventional human trials. However, cholecalciferol has been shown to decrease PWV in black youth normotensives with normal renal function.[200] These findings were not associated with any changes in iPTH or calcium, arguing for an effect of vitamin D not related to the classical effect on the mineral metabolism. We are currently investigating, whether the same effect will be found in Caucasian adults in winter month (clinicaltrials.gov NCT00952562). In the CKD patient the effect of vitamin D on arterial stiffness is even more complex to explore, because of the impaired activity of 1α-hydroxylase. An effect of vitamin D on the arterial system may be mediated through autocrine or paracrine effects of 25-hydroxyvitamin D after local 1α-hydroxylaion. Alternative, there may be an effect of the endocrine active 1,25-dihydroxyvitamin D. Or it may be a combination of both. Furthermore, a difference between the available vitamin D analogs may exist. Our data insinuate that, there could be a difference in the effect of these analogs. Likewise, in uremic rats doxercalciferol were found to increase PWV and in high dose to increase aortic calcification, whereas PWV and calcification was unchanged after paricalcitol treatment, although similar increases in phosphate and calcium was induced.[201]

There are several mechanisms through which vitamin D could influence on aortic stiffness, i.e. PWV and Aix, and mediate a cardiovascular protective effect as seen in observational studies.[202]

Vitamin D down-regulates the renin-angiotensin system (RAS) in animal studies by inhibiting the renin synthesis,[203;204] and suppress development and progression of renal insufficiency in uremic rats, with a synergistic effect to ACE-inhibitors and Angiotensin II antagonists.[205-207] A randomized placebo controlled trial has recently shown a dose dependent reduction in 24h-albuminuria excretion by paricalcitol in type 2 diabetics with albuminuria, which may be mediated through an inhibitory effect on RAS.[208] Furthermore, a controlled but not randomised study found a regression in myocardial hypertrophy in hemodialysis patients during calcitriol treatment, which also could be a RAS inhibitory effect.[209] In Dahl salt sensitive rats paricalcitol attenuated the salt induced left ventricular hypertrophy,[210] and in spontaneously hypertensive rats paricalcitol and doxercalciferol

	Period 1							Period 2						
	Alfacalcidol		Paricalcitol		Alfacalcidol	Paricalcitol		Alfacalcidol		Paricalcitol		Alfacalcidol	Paricalcitol	
	Week 6 Mean (SD) (n=26)	Week 22 Mean (SD) (n=26)	Week 6 Mean (SD) (n=31)	Week 22 Mean (SD) (n=31)	Increase Mean (SEM) (n=26)	Increase Mean (SEM) (n=31)	Difference between groups Mean (SEM)	Week 28 Mean (SD) (n=31)	Week 44 Mean (SD) (n=31)	Week28 Mean (SD) (n=26)	Week 44 Mean (SD) (n=26)	Increase Mean (SEM) (n=31)	Increase Mean (SEM) (n=26)	Difference between groups Mean (SEM)
Log FGF23	3.46 (0.66)	3.82 (0.51)	3.34 (0.70)	3.70 (0.56)	0.37 (0.07)*	0.36 (0.09)*	0.003 (0.118) P=0.978	3.49 (0.62)	3.89 (0.62)	3.47 (0.53)	3.73 (0.52)	0.26 (0.07)*	0.40 (0.06)*	0.136 (0.094) P=0.152
FGF23 (pg/ml)	6634.5 (7256.4)	10865.8 (8939.2)	6128.5 (8583.2)	9603.0 (12192.8)	4231.3 (945.0)*	7537.3 (1506.8)*	756.7 (1931.9) P=0.697	5621.0 (6400.9)	10108.6 (12613.2)	6231.6 (6487.7)	13768.9 (10639.3)	4487.6 (1538.1)*	3474.6 (1580.2)*	3049.7 (2174.0) P=0.166
PTH (pg/ml)	585.7 (246.5)	257.3 (190.6)	522.5 (174.9)	181.4 (137.0)	-328.5 (61.3)*	-341.1 (25.6)*	12.6 (62.7) P=0.851	457.1 (224.6)	277.3 (219.8)	492.5 (287.4)	388.6 (399.2)	-179.9 (39.3)*	-103.9 (55.6)	76.0 (66.5) P=0.258
Ionised calcium (mmol/l)	1.16 (0.08)	1.25 (0.09)	1.15 (0.08)	1.28 (0.10)	0.09 (0.02)*	0.13 (0.02)*	0.04 (0.02) P=0.098	1.17 (0.07)	1.24 (0.10)	1.18 (0.09)	1.27 (0.11)	0.07 (0.02)*	0.10 (0.03)*	0.03 (0.03) P=0.328
Phosphate (mmol/l)	1.50 (0.23)	1.65 (0.35)	1.49 (0.26)	1.57 (0.37)	0.14 (0.07)*	0.08 (0.07)	0.06 (0.10) P=0.521	1.47 (0.42)	1.66 (0.38)	1.42 (0.34)	1.66 (0.29)	0.17 (0.09)	0.24 (0.07)*	0.07 (0.12) P=0.598

Tabel 7
Changes in log FGF23, FGF23, PTH, ionised calcium and phosphate in patients enrolled in FGF23 study

reduced left ventricular hypertrophy, which was almost prevented when combined with losartan.211 An influence on the RAS could indeed affect the pulse wave velocity and morphology, as ACE-inhibitors and Angiotensin-II antagonist has been shown to reduce the central arterial stiffness.212

The influence of vitamin D on vascular calcification is still not fully explored. Calcium and phosphate stimulate vascular calcification,34;213 and as vitamin D increase calcium and phosphate it is an important side effect of vitamin D treatment, that targets the nephrologists in everyday practice. Observational studies214;215 has linked the use of vitamin D therapy to increased vascular calcification in CKD, whereas others have shown less calcification in vitamin D treated CKD patients.216 Both low and high 1,25-dihydroxyvitamin D levels have been associated with vascular calcification in paediatric hemodialysis patients.197 Vitamin D analogs, including calcitriol, alfacalcidol, and paricitol has been shown to induce vascular calcification in vivo and in vitro,217-221 although two comparative studies in uremic animals found no calcification in rat aorta, when treated with paricalcitol, whereas calcitriol and doxercalciferol induced calcification, independently of calcium-phosphate levels.222;223 It may be a question of dose, as in mice where treatment with low dose calcitriol and paricalcitol were protective against vascular calcification, whereas high dosages stimulated calcification.224

Only one interventional vitamin D study measured vascular calcification in CKD patients. In a five year randomized placebo controlled trial of intravenous calcitriol in 76 hemodialysis patients, extraskeletal calcifications were evaluated by x-ray of hand, foot, pelvis and chest. There was no difference in tendency to development or progression of vascular calcification.225

Additionally, vitamin D analogs may have anti-inflammatory properties.226 Inflammatory processes are known to play a role in the atherosclerotic process, and the malnutrition-inflammation complex are common in dialysis patients and is a risk factor for increased morbidity and mortality.227 Elevated inflammatory markers is associated with increased aortic PWV228-230 and anti-inflammatory therapy has been shown to decrease arterial stiffness.231

FGF23 is associated with arterial stiffness in subjects with reduced renal function.232 We did not find any significant correlation between baseline levels of FGF23 and baseline PWV (r = 0.77; P = 0.083) or Aix@HR75(r = -0.486; P = 0.154) in our small material (n = 14) nor did we find any correlation between changes in FGF23 and changes in PWV (r = 0.104; P = 0.790) or changes in Aix@HR75 (r = -0.248; P = 0.488) during the first treatment period. But the small sample size (n = 10) should be emphasised. Whether FGF23 has a direct influence on arterial stiffness and vascular calcification is a question for further research.233

CHANGES IN FGF23

We found a significant increase in FGF23 during treatment with alfacalcidol and paricalcitol (**Table 7**). The influence of alfacalcidol on FGF23 has never been described before, whereas paricalcitol has been shown to increase FGF23 in dialysis patients in one former study.234 There was no difference between treatment groups concerning the increase in FGF23. Interventional studies has consistently described an increased FGF23 during treatment with calcitriol,235 paricalcitol and doxercalciferol in adult hemodialysis patients,234 and of calcitriol and doxercalciferol in paediatric peritoneal dialysis patients,169 and in vitro studies has demonstrated a calcitriol induced increase in FGF23 expression in bone derived cell cultures.85;87;236

The interaction between FGF23 and the other factors in the mineral metabolism are presently unresolved. We explored this issue. We found baseline levels of FGF23, changes in phosphate, changes in ionised calcium and cumulative dose of vitamin D analog to be associated with changes in FGF23. If the multivariate analysis for repeated measures were performed with the mean final vitamin D analog dose instead of cumulative dose of vitamin D, the mean final dose were not found as a predictor of FGF23 change. This is in accordance with Nishi et al.235 which also found an association with cumulative dose of vitamin D analog and FGF23 changes, whereas Wetmore et al.234 and Wesseling-Perry et al.237 did not find any association with mean final dose of vitamin D analog. Whereas FGF23 has a halftime of minutes in patients with tumour induced osteomalacia and normal renal

Figure 4
Receiver operated curves (ROC) to detect the usefulness of FGF23, phosphate, ionised calcium and PTH to predict secondary hyperparathyroidism refractory to treatment with vitamin D analogs.

function,238 this may be prolonged in CKD patients as FGF23 is in some degree cleared by the kidneys.83 Therefore, there might be an accumulation of FGF23 proportional with the cumulative dose of vitamin D analogs.

The association between change in phosphate levels and change in FGF23 levels is expected as prolonged increase of phosphate load stimulates FGF23, although the exact mechanism remains to be determined.239 Furthermore, our data suggest a regulatory mechanism of calcium. The same association was described in former clinical studies,234;240 and was proposed in a sole experimental study.93 This mechanism remains to be further explored.

We found FGF23 to be an independent positive predictor for the final level of PTH after 16 weeks of treatment with any of the vitamin D analogs. In the study population of the FGF23 study, 25% of the patients never reached a PTH level beneath 300 pg/ml. FGF23 may be a screening tool in order to describe the candidates for treatment with vitamin D analog.241 Receiver operated curves for discriminating patients with refractory secondary hyperparathyroidism (PTH >300 pg/ml after 16 weeks of vitamin D analog treatment) are demonstrated in **Figure 4**. Area under curve obtained by FGF23 (AUC = 0.717; P = 0.016) was larger than phosphate (AUC = 0.700; P = 0.025), ionised calcium (AUC = 0.709; P = 0.019) and PTH (AUC = 0.600; P = 0.266).

It is possible that vitamin D analogs in addition to a direct and indirect (through elevated calcium levels) PTH suppression, also suppress PTH by increasing FGF23. Elevated baseline FGF23 may be a marker of parathyroid resistance to the PTH suppressive effect of FGF23 in the uremic patients.82 How to prevent this parathyroid resistance to FGF23 is a question for further research, but early intervention before parathyroid hyperplasia and autonomy evolves is probably of great importance.

CHANGES IN ALKALINE PHOSPHATASE

The physiological role of alkaline phosphatase is not fully understood, but alkaline phosphatase is essential for bone mineralisation.242 Elevated alkaline phosphatase is associated with secon-

dary hyperparathyroidism243 and renal osteodystrophy244 in dialysis patients. We did not find any significant changes in total alkaline phosphatase in any of the groups during treatment. This is opposite to the finding by other groups during treatment with alfacalcidol or paricalcitol,149;153;245-247 where a decrease in alkaline phosphatase were described even after 12 weeks of treatment in hemodialysis patients.153 Bone specific alkaline phosphatase is more specific in describing bone remodelling, than total alkaline phosphatase,248 and a change might have been observed if alkaline phosphatase had been fractionised.

Alkaline phosphatase >120 U/l has been associated with increased hospitalisation and mortality in hemodialysis patients independent of calcium, phosphate and PTH levels.249;250 Alkaline phosphatase >120 U/l was present in 17% (A: n = 5; P: n = 7) of the patients at baseline and 11% (A: n = 5; P: n = 4) after 16 weeks of treatment, with no overall difference during treatment (P = 0.183).

LEVELS OF 25 HYDROXYVITAMIN D AND 1,25-DIHYDROXYVITAMIN D

In the present study 25-hydroxyvitamin D deficiency (<50 nmol/l) was observed in 72% at baseline. In the Danish healthy population 42% has vitamin D deficiency in the wintertime.251 High prevalence of vitamin D deficiency has been reported among other CKD populations, especially in those with a GFR less than 30 ml/min/1.73m2.252-254 The reasons for this increased prevalence is probably multiple, including aging, diabetes, proteinuria, lack of sun exposure and decreased synthesis in the skin, decreased 25-hydroxylation by the liver of the uremic patient, and dietary restrictions.255-257 Furthermore, it is shown in healthy man that, 1,25-dihydroxyvitamin D may inhibit hepatic 25-hydroxylation.258

Treatment with vitamin D analogs did not influence on the level of 25-hydroxyvitamin D. However, six week wash out is too short to conclude about the influence of treatment versus no treatment on 25-hydroxyvitamin D, which has a half time of 18-25 days in normal man.259;260

Deficiency of 25-hydroxyvitamin D is associated with increased risk of mortality in non-dialysis CKD patients and incident hemodialysis patients.50;52 No randomised study has been performed evaluating whether substitution with cholecalciferol or ergocalciferol improves survival or other clinical endpoints in CKD patients. It is unknown whether this deficiency is sufficiently substituted by active vitamin D analogs. The presence of vitamin D 1α-hydroxylase and VDR in almost every tissue makes an autocrine-paracrine function of 25-hydroxyvitamin D possible.261-263 This may require substitution with native analogs to achieve the local effect. Apparently, 1,25-dihydroxyvitamin D levels are important for the local function of 25-hydroxyvitamin D in CKD patients, as in monocytes where 25-hydroxyvitamin D uptake is normalised after 1,25-dihydroxyvitamin D substitution.264 It seems likely that both should be supplemented in CKD patients.

The median 1,25-dihydroxyvitamin D level at baseline was 7 pmol/l (2.5-80) compared to the reported level of 105 pmol/l in subjects with GFR>80ml/min/1.73m2.3

In animal studies in 5/6 nephrectomised rats, paricalcitol decreased levels of 1,25-dihydroxyvitamin D.265 As 1,25-dihydroxyvitamin D exerts a negative feedback on its own synthesis,100 it was speculated that paricalcitol decrease 1,25-dihydroxyvitamin D synthesis through this feed-back mechanism. Contrary, we did not find any changes in 1,25-dihydroxyvitamin D

in the paricalcitol group, although 1,25-dihydroxyvitamin D was measured only in a small fraction of our participants. As expected the level of 1,25-dihydroxyvitamin D increased during treatment with alfacalcidol, because of the 25-hydroxylation of the drug.

CONCLUSION
This thesis describes a randomised 2 x 16 week cross-over study comparing alfacalcidol and paricalcitol in a group of Danish chronic hemodialysis patients with secondary hyperparathyroidism.

The main results were:

After forced titration of the vitamin D analogs, we found no difference in their ability to suppress secondary hyperparathyroidism, while keeping phosphate and ionised calcium inside the desired range

We found no difference in the incidence of hypercalcemia or hyperphosphatemia during 16 weeks of dose titration

We found a former not described interaction between baseline PTH and treatment. Pointing to alfacalcidol had an equal effect across all levels of PTH, while paricalcitol suppressed PTH better at lower PTH levels than at higher PTH levels

FGF23 increased significantly and equally during treatment with alfacalcidol and paricalcitol

FGF23 levels predicted PTH response to treatment with vitamin D analogs

Paricalcitol decreased pulse wave velocity, whereas alfacalcidol increased pulse wave velocity in a small group of patients. These results need to be confirmed, because of the small sample size with different baseline levels.

16 weeks of treatment with alfacalcidol or paricalcitol did not influence on the level of 25-hydroxyvitamin D

16 weeks of treatment with alfacalcidol increased 1,25-dihydroxyvitamin D, whereas the level was unchanged after paricalcitol treatment

On the basis of the present study, we find alfacalcidol and paricalcitol to be equal candidates, when treating mineral disturbances in patients with chronic kidney disease.

ABBREVIATIONS
AIx: Augmentation index
AIx@HR75: Augmentation index corrected to heart rate 75
AUC: Area under curve
aSR: calcium sensing receptor
CI: confidence interval
CKD: chronic kidney disease
CKD-MBD: chronic kidney disease – mineral and bone disorder
Cmax: Maximal concentration
CVD: cardiovascular disease
FGF23: fibroblast growth factor 23
GFR: glomerular filtration rate
HD: hemodialysis
iPTH: intact parathyroid hormone
PTH: parathyroid hormone
PWV: pulse wave velocity
RAS: renin angiotensin system
SHPT: secondary hyperparathyroidism
Tr: time to reflection
VDR: Vitamin D receptor

SUMMARY
Vitamin D analogs are used for treatment of secondary hyperparathyroidism in patients with chronic kidney disease in order to prevent renal osteodystrophy, bone fracture and pain. Calcium and phosphate levels increase with increasing doses of vitamin D analogs and are associated with increased risk of vascular calcification and cardiovascular morbidity and mortality. Therefore, in everyday clinical practice, hypercalcemia and hyperphosphatemia often limits the ability to suppress secondary hyperparathyroidism in patients with chronic kidney disease. In Denmark, alfacalcidol and paricalcitol are the most frequently used vitamin D analogs

The present thesis describes the first comparative study of alfacalcidol and paricalcitol and their ability to control the disturbances in the mineral metabolism in hemodialysis patients

In a multicenter randomised 2 x 16 week cross-over study (n = 86), with a 6 week wash out period preceding and between treatment periods, intravenous alfacalcidol and paricalcitol were given by forced titration (50% dose increase) every second week, until parathyroid hormone were sufficiently suppressed or ionised calcium and/or phosphate levels were elevated

Due to the presence of a period effect, only data from the initial 16-week intervention period (n = 80) were available for statistical tests of effect on parathyroid hormone. The proportion of patients achieving a 30% decrease in parathyroid hormone over the last four weeks was similar in the two groups (alfacalcidol 82%, paricalcitol 93% (P = 0.180)). A significant interaction effect between baseline parathyroid hormone and treatment was found (P = 0.012), suggesting the effects of alfacalcidol to be independent of baseline parathyroid hormone level, whereas paricalcitol to be more efficient at low than at high baseline levels. There were no differences in incidence of hypercalcemia and hyperphosphatemia.

FGF23 increases renal phosphate excretion and decreases levels of 1,25-dihydroxyvitamin D

FGF23 is elevated in hemodialysis patients by mechanisms not fully understood. We explored the influence of alfacalcidol and paricalcitol on FGF23 in stored blood samples from the beginning and the end of each treatment period. FGF23 increased significantly and equally during treatment with alfacalcidol and paricalcitol. Furthermore, we found baseline FGF23 to predict PTH levels after 16 weeks of vitamin D analog treatment.

Overall, alfacalcidol and paricalcitol are equal candidates for treatment of disturbances in mineral metabolism in hemodialysis patients.

REFERENCES
1. The Danish Society of Nephrology. Danish Nephrology Registry Annual Report 2009. 2010.
2. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; S1-130
3. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38

4. Nykjaer A, Dragun D, Walther D et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96: 507-515

5. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; doi:10.1038/ki.2011.47

6. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215

7. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-28

8. Usatii M, Rousseau L, Demers C et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis. Kidney Int 2007; 72: 1330-1335

9. Kumar R, Thompson JR. The Regulation of Parathyroid Hormone Secretion and Synthesis. J Am Soc Nephrol 2010; 2: 216-224

10. Brown AJ, Dusso A, Lopez-Hilker S, Lewis-Finch J, Grooms P, Slatopolsky E. 1,25-(OH)2D receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int 1989; 35: 19-23

11. Lewin E, Rodriguez M. Abnormal parathyroid gland function in CKD. In: Olgaard K, Salusky IB, Silver J, eds. The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Oxford University Press, 2010; 77-107

12. Martin KJ, Olgaard K, Coburn JW et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43: 558-565

13. Slatopolsky E, Gonzalez E, Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003; 21: 318-326

14. Coen G, Ballanti P, Bonucci E et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002; 91: 103-111

15. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26: 836-844

16. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156

17. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366

18. Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18: 2401-2407

19. Mitterbauer C, Kramar R, Oberbauer R. Age and sex are sufficient for predicting fractures occurring within 1 year of hemodialysis treatment. Bone 2007; 40: 516-521

20. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119

21. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305

22. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97

23. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617

24. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218

25. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138

26. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780

27. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528

28. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K. Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 468-476

29. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357

30. Naves-Diaz M, Passlick-Deetjen J, Guinsburg A et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2010; 10.1093/ndt/gfq304 [doi]

31. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005; 46: 68-77

32. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793

33. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530

34. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964

35. Goodman WG, London G, Amann K et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43: 572-579

36. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867

37. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483

38. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage re-

nal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701

39. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740

40. Miller JE, Kovesdy CP, Norris KC et al. Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol 2010; 32: 403-413

41. Carafoli E, Penniston JT. The calcium signal. Sci Am 1985; 253: 70-78

42. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003; 24: 2054-2060

43. Schluter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998; 37: 34-41

44. Jean G, Lataillade D, Genet L et al. Association between Very Low PTH Levels and Poor Survival Rates in Haemodialysis Patients: Results from the French ARNOS Cohort. Nephron Clin Pract 2010; 118: c211-c216

45. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835

46. Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38: 1351-1357

47. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201

48. Daugaard H, Heaf J, Joffe P et al. Forstyrrelser i knogle- og mineralomsætningen ved kronisk nyresygdom. Guidelines for diagnostik og behandling. 2005;

49. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-1127

50. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013

51. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2008; 75: 88-95

52. Mehrotra R, Kermah DA, Salusky IB et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009; 76: 977-983

53. Kilkkinen A, Knekt P, Aro A et al. Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol 2009; 170: 1032-1039

54. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637

55. Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511

56. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456

57. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184

58. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125

59. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865

60. Lee GH, Benner D, Regidor DL, Kalantar-Zadeh K. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 2007; 17: 38-44

61. Naves-Diaz M, varez-Hernandez D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078

62. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403

63. Shoben AB, Rudser KD, de B, I, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619

64. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-72

65. Shinaberger CS, Kopple JD, Kovesdy CP et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1769-1776

66. St Peter WL, Li S, Liu J, Gilbertson DT, Arneson TJ, Collins AJ. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis. Pharmacotherapy 2009; 29: 154-164

67. Sugiura S, Inaguma D, Kitagawa A et al. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol 2010; 14: 43-50 Jean G, Lataillade D, Genet L et al. Impact of Hypovitaminosis D and Alfacalcidol Therapy on Survival of Hemodialysis Patients: Results from the French ARNOS Study. Nephron Clin Pract 2010; 118: c204-c210

68. Jean G, Lataillade D, Genet L et al. Impact of Hypovitaminosis D and Alfacalcidol Therapy on Survival of Hemodialysis Patients: Results from the French ARNOS Study. Nephron Clin Pract 2010; 118: c204-c210

69. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2009; CD005633

70. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; CD008175

71. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730-1737

72. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152: 315-323

73. Kuro-o M. Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab 2008; 19: 239-245

74. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008

75. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 2004; 29: 91-99

76. Saito H, Kusano K, Kinosaki M et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate cotransport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278: 2206-2211

77. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293: F1577-F1583

78. Yoshida T, Fujimori T, Nabeshima Y. Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology 2002; 143: 683-689

79. Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125-131

80. Canalejo R, Canalejo A, Martinez-Moreno JM et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010; 21: 1125-1135

81. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218

82. Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77: 232-238

83. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279

84. Imanishi Y, Inaba M, Nakatsuka K et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65: 1943-1946

85. Barthel TK, Mathern DR, Whitfield GK et al. 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 2007; 103: 381-388

86. Ito M, Sakai Y, Furumoto M et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 2005; 288: E1101-E1109

87. Kolek OI, Hines ER, Jones MD et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005; 289: G1036-G1042

88. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-2549

89. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 2005; 36: 971-977

90. Wesseling-Perry K, Wolf M. FGF23 in renal failure. In: Olgaard K, Salusky IB, Silver J, eds. The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Oxford University Press, 2010; 405-415

91. Kawata T, Imanishi Y, Kobayashi K et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18: 2683-2688

92. Lopez I, Rodriguez-Ortiz ME, Almaden Y et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 2011; 10.1038/ki.2011.107 [doi] Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095

93. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095

94. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592

95. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796

96. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608

97. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552

98. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25: 3983-3989

99. Saarem K, Pedersen JI. 25-Hydroxylation of 1 alpha-hydroxyvitamin D-3 in rat and human liver. Biochim Biophys Acta 1985; 840: 117-126

100. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277: F157-F175

101. Dusso AS, Finch J, Brown A et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991; 72: 157-164

102. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81: 353-373

103. Somjen D, Weisman Y, Kohen F et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111: 1666-1671

104. Brandi L. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Dan Med Bull 2008; 55: 186-210

105. Hansen D, Brandi L, Rasmussen K. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol. BMC Nephrol 2009; 10: 28 Holick MF, Semmler EJ, Schnoes HK, DeLuca HF. 1 -Hydroxy derivative of vitamin D 3 : a highly potent analog of 1 ,25-dihydroxyvitamin D 3. Science 1973; 180: 190-191

106. Holick MF, Semmler EJ, Schnoes HK, DeLuca HF. 1 -Hydroxy derivative of vitamin D 3 : a highly potent analog of 1 ,25-dihydroxyvitamin D 3. Science 1973; 180: 190-191

107. Chalmers TM, Hunter JO, Davie MW, Szaz KF, Pelc B, Kodicek E. 1-Alpha-hydroxycholecalciferol as a substitute for the kidney hormone 1,25-dihydroxycholecalciferol in chronic renal failure. Lancet 1973; 2: 696-699

108. Madsen S. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3. Acta Med Scand Suppl 1980; 638:3-120.: 3-120

109. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990; 86: 1313-1319

110. Russell J, Lettieri D, Sherwood LM. Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986; 119: 2864-2866

111. Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrology (Carlton) 2011; 16: 277-284

112. Shigematsu T, Kawaguchi Y, Unemura S et al. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol. Intern Med 1993; 32: 695-701

113. Brandi L, Daugaard H, Tvedegaard E et al. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 1992; 12: 311-318

114. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 2004; 19: 870-876

115. Tougaard L, Sorensen E, Brochner-Mortensen J, Christensen MS, Rodbro P, Sorensen AW. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure. Lancet 1976; 1: 1044-1047

116. Brandi L, Egfjord M, Olgaard K. Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. Nephrol Dial Transplant 2002; 17: 829-842

117. Nielsen PK. A direct inhibitory effect of 1á-hydroxyvitamin D3 on PTH secretion from bovine parathyroid glands. J Am Soc Nephrol 1997; 8: 578A

118. Brown AJ, Ritter CS, Knutson JC, Strugnell SA. The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrol Dial Transplant 2006; 21: 644-650 Brandi L, Egfjord M, Olgaard K. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays. Nephron Clin Pract 2005; 99: c128-c137

119. Brandi L, Egfjord M, Olgaard K. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays. Nephron Clin Pract 2005; 99: c128-c137

120. Koike N, Ichikawa F, Nishii Y, Stumpf WE. Sustained osteoblast nuclear receptor binding of converted 1alpha, 25-dihydroxyvitamin D3 after administration of 3H-1alpha-hydroxyvitamin D3: a combined receptor autoradiography and radioassay time course study with comparison to 3H-1alpha, 25-dihydroxyvitamin D3. Calcif Tissue Int 1998; 63: 391-395

121. el-Reshaid K, el-Reshaid W, Sugathan T, al-Mohannadi S, Sivanandan R. Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. Am J Nephrol 1997; 17: 505-510

122. Kimura Y, Nakayama M, Kuriyama S, Watanabe S, Kawaguchi Y, Sakai O. Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis. Clin Nephrol 1991; 35: 72-77

123. Moe S, Wazny LD, Martin JE. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. Can J Clin Pharmacol 2008; 15: e36-e43

124. Arenas MD, Muray S, Egea JJ, Millan I, Amoedo L, Gil MT. Comparative study of the efficacy of calcitriol vis-a-vis alfacalcidol in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD). EDTA congres Istanbul June 2005 . 2005.

125. Arenas MD, Muray S, Amoedo ML, Egea JJ, Millan I, Gil MT. [A long-term comparative study of calcitriol versus alphacalcidol in patients with secondary hyperparathyroidism on hemodialysis]. Nefrologia 2006; 26: 226-233

126. Slatopolsky E, Finch J, Ritter C et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26: 852-860

127. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997; 30: 105-112

128. Szabo A, Merke J, Beier E, Mall G, Ritz E. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049-1056

129. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432

130. Martin KJ, Gonzalez EA, Gellens ME, Hamm LL, Abboud H, Lindberg J. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. Am J Kidney Dis 1998; 32: S61-S66

131. Greenbaum LA, Benador N, Goldstein SL et al. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 2007; 49: 814-823

132. Coyne D, Acharya M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276

133. Ross EA, Tian J, Abboud H et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008; 28: 97-106

134. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001; 56: 315-323

135. Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E. Differential effects of acute administration of 19-Nor-

1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002; 40: 1283-1288

136. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001; 38: S51-S56

137. Abdul Gafor AH, Saidin R, Loo CY et al. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Nephrology (Carlton) 2009; 14: 488-492

138. Mittman N, Desiraju B, Meyer KB, Chattopadhyay J, Avram MM. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney Int Suppl 2010; S33-S36

139. Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999; 10: 980-985

140. Nakane M, Fey TA, Dixon DB et al. Differential effects of Vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol 2006; 98: 72-77

141. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139: 279-284 Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62: 1277-1284

142. Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62: 1277-1284

143. Lund RJ, Andress DL, Amdahl M, Williams LA, Heaney RP. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol 2010; 31: 165-170

144. Bailie GR, Johnson CA. Comparative review of the pharmacokinetics of vitamin D analogues. Semin Dial 2002; 15: 352-357

145. Dusso A, Tokumoto A, Brown A, Slatopolsky E. New vitamin D analogs for chronic kidney disease patients. In: Olgaard K, Salusky IB, Silver J, eds. The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Oxford University Press, New York: 2010; 417-441

146. Fernstr MA, Gi VJ, Granroth B et al. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study. Scand J Urol Nephrol 2011;

147. Vervloet MG, Grooteman MP, Wee PMT. Improvde parathyroid hormone levels after conversion from intravenous alfacalcidol to intravenous paricalcitol. ASN Renal Week Meeting . 2006.

148. Frandsen NE, Hansen D, Ostergaard OV. Effect of Paricalcitol on moderate-severe Hyperparathyroidism in chronic hemodialysis patients. ASN Renal Week Meeting . 2008.

149. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490

150. Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. Nephron 1996; 74: 89-103

151. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38: S45-S50

152. Abboud H, Coyne D, Smolenski O et al. A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. Am J Nephrol 2006; 26: 105-114

153. Llach F, Keshav G, Goldblat MV et al. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 1998; 32: S48-S54

154. Barreto FC, Barreto DV, Moyses RM et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777

155. D'Amour P, Brossard JH. Carboxyl-terminal parathyroid hormone fragments: role in parathyroid hormone physiopathology. Curr Opin Nephrol Hypertens 2005; 14: 330-336

156. Gao P, D'Amour P. Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab 2005; 51: 21-29

157. D'Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003; 49: 2037-2044

158. Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006; 70: 345-350

159. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2010; 77: 93-100

160. D'Amour P, Brossard JH, Rakel A, Rousseau L, Albert C, Cantor T. Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem 2005; 51: 169-176

161. Joly D, Drueke TB, Alberti C et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008; 51: 987-995

162. Schmitt CP, Homme M, Schaefer F. Structural organization and biological relevance of oscillatory parathyroid hormone secretion. Pediatr Nephrol 2005; 20: 346-351

163. Lips P, Chapuy MC, Dawson-Hughes B, Pols HA, Holick MF. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999; 9: 394-397

164. Wallace AM, Gibson S, de la Hunty A, Lamberg-Allardt C, Ashwell M. Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids 2010; 75: 477-488

165. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348: 1656-1663

166. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95: 578-585

167. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21: 1187-1196 Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of

chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608

168. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608

169. Wesseling-Perry K, Pereira RC, Sahney S et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011; 79: 112-119

170. Weber T, Ammer M, Rammer M et al. Noninvasive determination of carotid-femoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J Hypertens 2009; 27: 1624-1630

171. SphygmoCor Concise Software Guide. (2008). 2011. www.atcormedical.com

172. Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S. Pulse-wave morphology and pulse-wave velocity in healthy human volunteers: examination conditions. Scand J Clin Lab Invest 2006; 66: 385-394

173. Laurent S, Cockcroft J, Van BL et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605

174. Hommel K, Rasmussen S, Kamper AL, Madsen M. Regional and social inequalities in chronic renal replacement therapy in Denmark. Nephrol Dial Transplant 2010; 25: 2624-2632

175. Brown AJ, Zhong M, Finch J, Ritter C, Slatopolsky E. The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands. Endocrinology 1995; 136: 1419-1425

176. Wiese RJ, Uhland-Smith A, Ross TK, Prahl JM, DeLuca HF. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992; 267: 20082-20086

177. Brown AJ, Zhong M, Finch J et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996; 270: F454-F460

178. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525

179. Fishbane S, Shapiro WB, Corry DB et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3: 1718-1725

180. Vulpio C, Maresca G, Distasio E et al. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size. Hemodial Int 2011; 10.1111/j.1542-4758.2010.00514.x [doi] Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996; 11: 2430-2438

181. Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996; 11: 2430-2438

182. Bergwitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010; 61: 91-104

183. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16: 200-257

184. Panda DK, Miao D, Bolivar I et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279: 16754-16766

185. Issa LL, Leong GM, Sutherland RL, Eisman JA. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res 2002; 17: 879-890

186. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780

187. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000; 11: 1141-1152

188. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443

189. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994; 68: 221-228

190. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942

191. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38: 434-438

192. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021

193. Covic A, Haydar AA, Bhamra-Ariza P, Gusbeth-Tatomir P, Goldsmith DJ. Aortic pulse wave velocity and arterial wave reflections predict the extent and severity of coronary artery disease in chronic kidney disease patients. J Nephrol 2005; 18: 388-396 London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620

194. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620

195. Shiota J, Watanabe M. [Association of mineral and bone disorder with increasing PWV in CKD 1-5 patients]. Nippon Jinzo Gakkai Shi 2007; 49: 121-124

196. Andrade J, Er L, Ignaszewski A, Levin A. Exploration of association of 1,25-OH2D3 with augmentation index, a composite measure of arterial stiffness. Clin J Am Soc Nephrol 2008; 3: 1800-1806

197. Shroff R, Egerton M, Bridel M et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008; 19: 1239-1246

198. Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S. Reproducibility of pulse-wave analysis and pulse-wave velocity determination in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 594-600

199. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824

200. Dong Y, Stallmann-Jorgensen IS, Pollock NK et al. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab 2010; 95: 4584-4591

201. Noonan W, Koch K, Nakane M et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant 2008; 23: 3824-3830

202. Hansen D, Brandi L, Rasmussen K. [Vitamin D, cardiovascular disease and mortality in patients with kidney disease]. Ugeskr Laeger 2009; 171: 3684-3689

203. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003; 88: 327-331

204. Yuan W, Pan W, Kong J et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-29830

205. Mizobuchi M, Morrissey J, Finch JL et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806

206. Deb DK, Sun T, Wong KE et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 2010; 77: 1000-1009 Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008; 105: 15896-15901

207. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008; 105: 15896-15901

208. de ZD, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551

209. Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81

210. Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 2007; 104: 16810-16815

211. Kong J, Kim GH, Wei M et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 2010; 177: 622-631

212. Mahmud A, Feely J. Arterial stiffness and the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2004; 5: 102-108

213. Reynolds JL, Skepper JN, McNair R et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005; 16: 2920-2930

214. Briese S, Wiesner S, Will JC et al. Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. Nephrol Dial Transplant 2006; 21: 1906-1914

215. Shroff RC, Donald AE, Hiorns MP et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18: 2996-3003

216. Ogawa T, Ishida H, Akamatsu M et al. Relation of oral 1alpha-hydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients. Heart Vessels 2010; 25: 1-6

217. Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998; 98: 1302-1306

218. Krog M, Ejerblad S, Eriksson I, Johansson H. Arterial calcifications in uraemic rats treated with 1-alpha-hydroxycholecalciferol and parathyroidectomy. Scand J Urol Nephrol 1984; 18: 227-239

219. Krog M, Ejerblad S, Ericsson JL. Uraemic and 1-alpha-hydroxycholecalciferol induced aortic lesions. Exp Pathol 1988; 35: 101-114

220. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307

221. Shalhoub V, Shatzen E, Henley C et al. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int 2006; 79: 431-442

222. Cardus A, Panizo S, Parisi E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-866

223. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715

224. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509-1519

225. Baker LR, Muir JW, Sharman VL et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 1986; 26: 185-191

226. Alborzi P, Patel NA, Peterson C et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255

227. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808

228. Porazko T, Kuzniar J, Kusztal M et al. Increased aortic wall stiffness associated with low circulating fetuin A and high C-reactive protein in predialysis patients. Nephron Clin Pract 2009; 113: c81-c87

229. Provan SA, Angel K, Semb AG et al. Early Prediction of Increased Arterial Stiffness in Patients with Chronic Inflammation: A 15-year Followup Study of 108 Patients with Rheumatoid Arthritis. J Rheumatol 2011; 38: 606-12

230. Stompor T, Rajzer M, Sulowicz W et al. An association between aortic pulse wave velocity, blood pressure and chronic inflammation in ESRD patients on peritoneal dialysis. Int J Artif Organs 2003; 26: 188-195

231. Maki-Petaja KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des 2009; 15: 290-303

232. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-390

233. Larsson TE. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant 2010; 25: 1376-1381 Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116

234. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116

235. Nishi H, Nii-Kono T, Nakanishi S et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005; 101: c94-c99

236. Saji F, Shigematsu T, Sakaguchi T et al. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 2010; 299: F1212-F1217

237. Wesseling-Perry K, Pereira RC, Wang H et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94: 511-517

238. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 4957-4960

239. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21: 1427-1435

240. Cancela AL, Oliveira RB, Graciolli FG et al. Fibroblast Growth Factor 23 in Hemodialysis Patients: Effects of Phosphate Binder, Calcitriol and Calcium Concentration in the Dialysate. Nephron Clin Pract 2010; 117: c74-c82

241. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005; 67: 1120-1125

242. Weiss MJ, Ray K, Henthorn PS, Lamb B, Kadesch T, Harris H. Structure of the human liver/bone/kidney alkaline phosphatase gene. J Biol Chem 1988; 263: 12002-12010

243. Jorna FH, Tobe TJ, Huisman RM, de Jong PE, Plukker JT, Stegeman CA. Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy. Nephrol Dial Transplant 2004; 19: 1168-1173

244. Fletcher S, Jones RG, Rayner HC et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997; 75: 412-419

245. Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358-363

246. Pierides AM, Skillen AW, Ellis HA. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1alphaOHD3 and 1,25(OH)2D3. J Lab Clin Med 1979; 93: 899-909 Shimamatsu K, Maeda T, Harada A et al. 1-year controlled trial of 1 alpha-hydroxycholecalciferol in patients on maintenance hemodialysis. Nephron 1981; 28: 70-75

247. Shimamatsu K, Maeda T, Harada A et al. 1-year controlled trial of 1 alpha-hydroxycholecalciferol in patients on maintenance hemodialysis. Nephron 1981; 28: 70-75

248. Urena P, de Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156

249. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008; 74: 655-663

250. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203

251. Mosekilde L, Brot C, Hyldstrup L et al. [The vitamin D status of the Danish population needs to be improved]. Ugeskr Laeger 2005; 167: 895-897

252. Del VE, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007; 11: 315-321

253. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503-510

254. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: c132-c138

255. Cuppari L, Garcia Lopes MG, Kamimura MA. Vitamin D biology: from the discovery to its significance in chronic kidney disease. J Ren Nutr 2011; 21: 113-116

256. Jacob AI, Sallman A, Santiz Z, Hollis BW. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr 1984; 114: 1313-1319

257. Michaud J, Naud J, Ouimet D et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 2010; 21: 1488-1497

258. Bell NH, Shaw S, Turner RT. Evidence that 1,25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitamin D in man. J Clin Invest 1984; 74: 1540-1544

259. Haddad JG, Stamp TC. Circulating 25-hydroxyvitamin D in man. Am J Med 1974; 57: 57-62

260. Smith JE, Goodman DS. The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J Clin Invest 1971; 50: 2159-2167

261. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281

262. Holick MF. Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am 2010; 39: 381-400

263. Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206: 1188-1190

264. Gallieni M, Kamimura S, Ahmed A et al. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 1995; 268: F746-F753

265. Repo JM, Rantala IS, Honkanen TT et al. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 2007; 72: 977-984